WO2001091798A2 - Tumor activated prodrug compounds - Google Patents
Tumor activated prodrug compounds Download PDFInfo
- Publication number
- WO2001091798A2 WO2001091798A2 PCT/EP2001/006106 EP0106106W WO0191798A2 WO 2001091798 A2 WO2001091798 A2 WO 2001091798A2 EP 0106106 W EP0106106 W EP 0106106W WO 0191798 A2 WO0191798 A2 WO 0191798A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- prodrug
- prodrug according
- biologically active
- peptide
- leu
- Prior art date
Links
- 239000000651 prodrug Substances 0.000 title claims abstract description 347
- 229940002612 prodrug Drugs 0.000 title claims abstract description 347
- 206010028980 Neoplasm Diseases 0.000 title claims description 117
- 150000001875 compounds Chemical class 0.000 title abstract description 48
- 125000005647 linker group Chemical group 0.000 claims abstract description 206
- 230000000873 masking effect Effects 0.000 claims abstract description 123
- 238000001727 in vivo Methods 0.000 claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 40
- 239000000203 mixture Substances 0.000 claims abstract description 34
- 230000001988 toxicity Effects 0.000 claims abstract description 24
- 231100000419 toxicity Toxicity 0.000 claims abstract description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 286
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 125
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 124
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 124
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 111
- 230000009977 dual effect Effects 0.000 claims description 102
- 230000000694 effects Effects 0.000 claims description 86
- 238000003776 cleavage reaction Methods 0.000 claims description 68
- 230000007017 scission Effects 0.000 claims description 68
- 229960004679 doxorubicin Drugs 0.000 claims description 65
- 229920001223 polyethylene glycol Polymers 0.000 claims description 55
- 229920001184 polypeptide Polymers 0.000 claims description 55
- 239000002202 Polyethylene glycol Substances 0.000 claims description 51
- 239000005557 antagonist Substances 0.000 claims description 47
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 41
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 39
- 150000001413 amino acids Chemical group 0.000 claims description 39
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 39
- -1 dimethylmaleyl Chemical group 0.000 claims description 38
- 102000035195 Peptidases Human genes 0.000 claims description 37
- 108091005804 Peptidases Proteins 0.000 claims description 37
- 102000001398 Granzyme Human genes 0.000 claims description 31
- 108060005986 Granzyme Proteins 0.000 claims description 31
- 230000000295 complement effect Effects 0.000 claims description 24
- 239000003890 substance P antagonist Substances 0.000 claims description 21
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 20
- 238000000338 in vitro Methods 0.000 claims description 19
- 229920000642 polymer Polymers 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- 108010054982 alanyl-leucyl-alanyl-leucine Proteins 0.000 claims description 17
- 230000002101 lytic effect Effects 0.000 claims description 17
- KQRHTCDQWJLLME-XUXIUFHCSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N KQRHTCDQWJLLME-XUXIUFHCSA-N 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 16
- 125000006850 spacer group Chemical group 0.000 claims description 15
- 150000008574 D-amino acids Chemical class 0.000 claims description 14
- 108700012411 TNFSF10 Proteins 0.000 claims description 14
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 claims description 14
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 13
- FSBIGDSBMBYOPN-VKHMYHEASA-N L-canavanine Chemical compound OC(=O)[C@@H](N)CCONC(N)=N FSBIGDSBMBYOPN-VKHMYHEASA-N 0.000 claims description 12
- 239000004365 Protease Substances 0.000 claims description 12
- 230000000259 anti-tumor effect Effects 0.000 claims description 11
- 230000012010 growth Effects 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 9
- 102000006992 Interferon-alpha Human genes 0.000 claims description 9
- 108010047761 Interferon-alpha Proteins 0.000 claims description 9
- 108010002352 Interleukin-1 Proteins 0.000 claims description 9
- 102000000589 Interleukin-1 Human genes 0.000 claims description 9
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 9
- 229960000975 daunorubicin Drugs 0.000 claims description 9
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims description 9
- 239000000758 substrate Substances 0.000 claims description 9
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- 108090001005 Interleukin-6 Proteins 0.000 claims description 8
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 8
- 239000003207 proteasome inhibitor Substances 0.000 claims description 8
- AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 claims description 7
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 7
- 108010006654 Bleomycin Proteins 0.000 claims description 7
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 7
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 claims description 7
- 102100037850 Interferon gamma Human genes 0.000 claims description 7
- 108010074328 Interferon-gamma Proteins 0.000 claims description 7
- 229930192392 Mitomycin Natural products 0.000 claims description 7
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 7
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims description 7
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 claims description 7
- 229940122803 Vinca alkaloid Drugs 0.000 claims description 7
- 229960005305 adenosine Drugs 0.000 claims description 7
- 229960001561 bleomycin Drugs 0.000 claims description 7
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 7
- 229960005501 duocarmycin Drugs 0.000 claims description 7
- 229930184221 duocarmycin Natural products 0.000 claims description 7
- 229930013356 epothilone Natural products 0.000 claims description 7
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 7
- 229960005304 fludarabine phosphate Drugs 0.000 claims description 7
- 150000002224 folic acids Chemical class 0.000 claims description 7
- 230000003834 intracellular effect Effects 0.000 claims description 7
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 7
- 229960001924 melphalan Drugs 0.000 claims description 7
- 229960004857 mitomycin Drugs 0.000 claims description 7
- 229960001156 mitoxantrone Drugs 0.000 claims description 7
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 7
- 150000003057 platinum Chemical class 0.000 claims description 7
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 claims description 7
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 6
- 102000000588 Interleukin-2 Human genes 0.000 claims description 6
- 102000004889 Interleukin-6 Human genes 0.000 claims description 6
- FSBIGDSBMBYOPN-UHFFFAOYSA-N O-guanidino-DL-homoserine Natural products OC(=O)C(N)CCON=C(N)N FSBIGDSBMBYOPN-UHFFFAOYSA-N 0.000 claims description 6
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 claims description 6
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 claims description 5
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 claims description 5
- 102000011727 Caspases Human genes 0.000 claims description 5
- 108010076667 Caspases Proteins 0.000 claims description 5
- LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 108700031308 Antennapedia Homeodomain Proteins 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 4
- 102000053642 Catalytic RNA Human genes 0.000 claims description 4
- 108090000994 Catalytic RNA Proteins 0.000 claims description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- 102000002938 Thrombospondin Human genes 0.000 claims description 4
- 108060008245 Thrombospondin Proteins 0.000 claims description 4
- 230000003172 anti-dna Effects 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 108091092562 ribozyme Proteins 0.000 claims description 4
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 3
- 101710132316 Transactivation protein Proteins 0.000 claims description 3
- 108010088751 Albumins Proteins 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 2
- 102000004961 Furin Human genes 0.000 claims description 2
- 108090001126 Furin Proteins 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims description 2
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims description 2
- 229940000635 beta-alanine Drugs 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 4
- XUNKPNYCNUKOAU-VXJRNSOOSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]a Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XUNKPNYCNUKOAU-VXJRNSOOSA-N 0.000 claims 2
- AUXMWYRZQPIXCC-KNIFDHDWSA-N (2s)-2-amino-4-methylpentanoic acid;(2s)-2-aminopropanoic acid Chemical compound C[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O AUXMWYRZQPIXCC-KNIFDHDWSA-N 0.000 claims 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 2
- 108010079882 Bax protein (53-86) Proteins 0.000 claims 2
- 108091028026 C-DNA Proteins 0.000 claims 2
- 239000000074 antisense oligonucleotide Substances 0.000 claims 2
- 238000012230 antisense oligonucleotides Methods 0.000 claims 2
- 229960002685 biotin Drugs 0.000 claims 2
- 235000020958 biotin Nutrition 0.000 claims 2
- 239000011616 biotin Substances 0.000 claims 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims 2
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 claims 2
- 125000003974 3-carbamimidamidopropyl group Chemical group C(N)(=N)NCCC* 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 abstract description 11
- 210000004027 cell Anatomy 0.000 description 182
- 230000032258 transport Effects 0.000 description 79
- 239000000562 conjugate Substances 0.000 description 46
- 210000004881 tumor cell Anatomy 0.000 description 42
- 229940024606 amino acid Drugs 0.000 description 36
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 36
- 235000001014 amino acid Nutrition 0.000 description 31
- 125000003277 amino group Chemical group 0.000 description 28
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 28
- 230000001472 cytotoxic effect Effects 0.000 description 28
- 231100000433 cytotoxic Toxicity 0.000 description 27
- 230000004071 biological effect Effects 0.000 description 25
- 235000019833 protease Nutrition 0.000 description 25
- 238000003556 assay Methods 0.000 description 24
- 201000011510 cancer Diseases 0.000 description 23
- 230000001085 cytostatic effect Effects 0.000 description 21
- 102000007614 Thrombospondin 1 Human genes 0.000 description 20
- 108010046722 Thrombospondin 1 Proteins 0.000 description 20
- 210000004899 c-terminal region Anatomy 0.000 description 20
- 150000003384 small molecules Chemical class 0.000 description 20
- 230000001225 therapeutic effect Effects 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 19
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 238000009472 formulation Methods 0.000 description 18
- 230000015556 catabolic process Effects 0.000 description 17
- 238000006731 degradation reaction Methods 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 239000000824 cytostatic agent Substances 0.000 description 16
- 210000004940 nucleus Anatomy 0.000 description 15
- 210000000170 cell membrane Anatomy 0.000 description 14
- 210000002889 endothelial cell Anatomy 0.000 description 14
- 230000007420 reactivation Effects 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 230000004913 activation Effects 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 13
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 239000003636 conditioned culture medium Substances 0.000 description 12
- 230000001976 improved effect Effects 0.000 description 12
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 11
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 239000013543 active substance Substances 0.000 description 10
- 230000000118 anti-neoplastic effect Effects 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 206010029113 Neovascularisation Diseases 0.000 description 9
- 101710149951 Protein Tat Proteins 0.000 description 9
- 230000001093 anti-cancer Effects 0.000 description 9
- 230000021615 conjugation Effects 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 230000000973 chemotherapeutic effect Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 231100000331 toxic Toxicity 0.000 description 8
- 230000002588 toxic effect Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 7
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 239000004472 Lysine Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 7
- 235000019419 proteases Nutrition 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 206010059866 Drug resistance Diseases 0.000 description 6
- LSPYFSHXDAYVDI-SRVKXCTJSA-N Leu-Ala-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(C)C LSPYFSHXDAYVDI-SRVKXCTJSA-N 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 230000005945 translocation Effects 0.000 description 6
- 230000000381 tumorigenic effect Effects 0.000 description 6
- RDIKFPRVLJLMER-BQBZGAKWSA-N Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)N RDIKFPRVLJLMER-BQBZGAKWSA-N 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 230000001461 cytolytic effect Effects 0.000 description 5
- 238000001212 derivatisation Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 231100000518 lethal Toxicity 0.000 description 5
- 230000001665 lethal effect Effects 0.000 description 5
- 231100000225 lethality Toxicity 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000036515 potency Effects 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 238000004007 reversed phase HPLC Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 231100000588 tumorigenic Toxicity 0.000 description 5
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
- HSQGMTRYSIHDAC-BQBZGAKWSA-N Leu-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(O)=O HSQGMTRYSIHDAC-BQBZGAKWSA-N 0.000 description 4
- XIRYQRLFHWWWTC-QEJZJMRPSA-N Leu-Ala-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 XIRYQRLFHWWWTC-QEJZJMRPSA-N 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 239000012082 adaptor molecule Substances 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000001028 anti-proliverative effect Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 150000001576 beta-amino acids Chemical class 0.000 description 4
- 238000007385 chemical modification Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 108010071185 leucyl-alanine Proteins 0.000 description 4
- 108010076756 leucyl-alanyl-phenylalanine Proteins 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- 238000011894 semi-preparative HPLC Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 238000001542 size-exclusion chromatography Methods 0.000 description 4
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 3
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 3
- 229930028154 D-arginine Natural products 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 102000015636 Oligopeptides Human genes 0.000 description 3
- 108010038807 Oligopeptides Proteins 0.000 description 3
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 3
- 229920000249 biocompatible polymer Polymers 0.000 description 3
- 238000000423 cell based assay Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 229940125878 compound 36 Drugs 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000001917 fluorescence detection Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000005714 functional activity Effects 0.000 description 3
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 239000000863 peptide conjugate Substances 0.000 description 3
- 229930192851 perforin Natural products 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000001525 receptor binding assay Methods 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 2
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
- JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid Chemical compound [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 description 2
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
- 108020004491 Antisense DNA Proteins 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000018389 Exopeptidases Human genes 0.000 description 2
- 108010091443 Exopeptidases Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 108010036176 Melitten Proteins 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 101800003906 Substance P Proteins 0.000 description 2
- 102400000096 Substance P Human genes 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000009056 active transport Effects 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229960002684 aminocaproic acid Drugs 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 229940127093 camptothecin Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 150000002613 leucine derivatives Chemical class 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 150000003141 primary amines Chemical group 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000011896 sensitive detection Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 231100000004 severe toxicity Toxicity 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000006104 solid solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical group OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 231100000057 systemic toxicity Toxicity 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- 238000011191 terminal modification Methods 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229960000834 vinyl ether Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- ZMXDCSXZDFHSEH-YFKPBYRVSA-N (2s)-2-amino-4-(1-aminoethylideneamino)oxybutanoic acid Chemical compound CC(=N)NOCC[C@H](N)C(O)=O ZMXDCSXZDFHSEH-YFKPBYRVSA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- SRKGZXIJDGWVAI-GVAVTCRGSA-M (e,3r)-7-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)C1=NC(C(C)(C)C)=CC(C=2C=CC(F)=CC=2)=C1\C=C\C(O)C[C@@H](O)CC([O-])=O SRKGZXIJDGWVAI-GVAVTCRGSA-M 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- MFGALGYVFGDXIX-UHFFFAOYSA-N 2,3-Dimethylmaleic anhydride Chemical group CC1=C(C)C(=O)OC1=O MFGALGYVFGDXIX-UHFFFAOYSA-N 0.000 description 1
- VHSHLMUCYSAUQU-UHFFFAOYSA-N 2-hydroxypropyl methacrylate Chemical compound CC(O)COC(=O)C(C)=C VHSHLMUCYSAUQU-UHFFFAOYSA-N 0.000 description 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- GNSFRPWPOGYVLO-UHFFFAOYSA-N 3-hydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCO GNSFRPWPOGYVLO-UHFFFAOYSA-N 0.000 description 1
- OMNVYXHOSHNURL-WPRPVWTQSA-N Ala-Phe Chemical group C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OMNVYXHOSHNURL-WPRPVWTQSA-N 0.000 description 1
- 102000008076 Angiogenic Proteins Human genes 0.000 description 1
- 108010074415 Angiogenic Proteins Proteins 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 101710115643 Cathelicidin-1 Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 125000002038 D-arginyl group Chemical group N[C@@H](C(=O)*)CCCNC(=N)N 0.000 description 1
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 1
- 229930182819 D-leucine Natural products 0.000 description 1
- 125000003301 D-leucyl group Chemical group N[C@@H](C(=O)*)CC(C)C 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 231100001074 DNA strand break Toxicity 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical group CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 229940124226 Farnesyltransferase inhibitor Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 208000012766 Growth delay Diseases 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 101000573199 Homo sapiens Protein PML Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical compound C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 108091002531 OF-1 protein Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 229920000037 Polyproline Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010057517 Strep-avidin conjugated horseradish peroxidase Proteins 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 229940123468 Transferase inhibitor Drugs 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical class 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Natural products NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- WPJRFCZKZXBUNI-HCWXCVPCSA-N daunosamine Chemical group C[C@H](O)[C@@H](O)[C@@H](N)CC=O WPJRFCZKZXBUNI-HCWXCVPCSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- GWNFQAKCJYEJEW-UHFFFAOYSA-N ethyl 3-[8-[[4-methyl-5-[(3-methyl-4-oxophthalazin-1-yl)methyl]-1,2,4-triazol-3-yl]sulfanyl]octanoylamino]benzoate Chemical compound CCOC(=O)C1=CC(NC(=O)CCCCCCCSC2=NN=C(CC3=NN(C)C(=O)C4=CC=CC=C34)N2C)=CC=C1 GWNFQAKCJYEJEW-UHFFFAOYSA-N 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000054896 human PML Human genes 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- HROXIDVVXKDCBD-ZUWKMVCBSA-N leurubicin Chemical class O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](NC(=O)[C@@H](N)CC(C)C)[C@H](O)[C@H](C)O1 HROXIDVVXKDCBD-ZUWKMVCBSA-N 0.000 description 1
- 231100001106 life-threatening toxicity Toxicity 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001576 membenolytic effect Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- QVDXUKJJGUSGLS-LURJTMIESA-N methyl L-leucinate Chemical compound COC(=O)[C@@H](N)CC(C)C QVDXUKJJGUSGLS-LURJTMIESA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 108010094020 polyglycine Proteins 0.000 description 1
- 229920000232 polyglycine polymer Polymers 0.000 description 1
- 108010026466 polyproline Proteins 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000029983 protein stabilization Effects 0.000 description 1
- 239000001990 protein-drug conjugate Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 238000003751 purification from natural source Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000001768 subcellular fraction Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000008791 toxic response Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 239000003558 transferase inhibitor Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Definitions
- the present invention relates to novel prodrug compounds, to pharmaceutical compositions comprising the novel prodrug compounds and to methods of using the compounds to inhibit the growth of tumors and/or to treat malignant tumors and/or tumorigenic cancers.
- Cancer is currently the second largest killer in the developed world with more than 6 million deaths per year, a figure that is expected to double by 2022. Despite efforts to improve the efficacy of treatments, relatively low cure rates have been achieved to date. Current attempts at cancer therapy suffer from several major deficiencies. First, most available cancer therapies consist of drugs that act on rapidly dividing cells.
- New cytotoxic drugs are regularly entering the clinic but their use remains hampered by their toxic side effects, the high rate of induced resistance and, in some instances, their poor blood stability.
- extracellularly active entities and polypeptides have recently been identified that have cytotoxic or cytostatic effects on tumor cells in vitro and/or in vivo.
- TNF ⁇ a cytokine with diverse effects on cells both in vitro and in vivo, exhibits cytotoxic and cytostatic effects on tumor cell types in vitro.
- the growth of many normal cell types such as endothelial cells, smooth muscle cells, adipocytes, fibroblasts and keratinocytes is also inhibited by TNF ⁇ in vitro.
- TNF ⁇ Sensitivity of human endothelial cells to TNF ⁇ correlates with their rate of proliferation.
- Multiple clinical studies phase I and II have been carried out with recombinant TNF ⁇ as an anticancer entity without major therapeutic effect.
- TNF ⁇ -induced systemic toxicity and acquired resistance to TNF ⁇ are two major roadblocks towards the success of TNF ⁇ as an antineoplastic entity.
- antineoplastic entities for use in treating solid tumor types.
- antineoplastic entities that exhibit some degree of selectivity and/or specificity for tumor cells or that can be delivered at dosages that achieve therapeutic benefit with little or no toxicity.
- the present invention provides novel prodrug compounds that have improved therapeutic properties.
- the novel prodrugs comprise a biologically active entity linked to a masking moiety via a linking moiety.
- the biologically active entities can be administered to tumor cells and to endothelial cells involved in tumor neoangiogenesis in a selective manner.
- the prodrugs of the invention will typically exhibit lower toxicity and possibly a longer in vivo or serum half-life than the corresponding naked biologically active entity.
- the invention is based, in part, on the discovery that peptides having certain amino acid sequences are specifically cleaved by proteases and/or peptidases in the extracellular medium at or near tumor cells and certain endothelial cells involved in neoangiogenesis ("target cells").
- target cells certain endothelial cells involved in neoangiogenesis
- peptides that may be specifically cleaved in the target extracellular milieu include those having the amino acid sequence (Leu) y (Ala- Leu) x Ala-Leu and (Leu) y (Ala-Leu) x Ala-Phe, where y is 0 or 1 and x is 1 , 2 or 3.
- the peptidase that cleaves the linking moiety is not unique to tumors or tumor cells. Healthy cells also produce peptidases capable of cleaving the linking moiety. However, it has been discovered that significantly more cleavage is observed around tumor cells. While not intending to be bound by any particular theory of operation, it is believed that tumor cells excrete significantly higher concentrations of the cleaving peptidases than do healthy cells, which accounts for the observed higher cleavage in their vicinity. Thus, while the peptidases are not unique to tumors or tumor cells, the prodrugs of the present invention exploit the observed differences in cleavage surrounding tumor cells and healthy cells to selectively deliver biologically active entities to tumor cells.
- the prodrugs of the invention permit compounds that are cytotoxic or cytostatic to be selectively delivered to the target cells, thereby providing a selective and safe means of delivering the cytotoxic and/or cytostatic agents to patients to treat tumorigenic conditions, such as malignant tumorigenic cancers.
- the masking moiety of the prodrugs is linked to the biologically active entity via the linking moiety.
- the masking moiety acting alone or together with the linking moiety, blocks or inhibits the biological activity of the biologically active entity.
- the masking moiety prevents non-specific degradation and/or cleavage of the linking moiety by, for instance, peptidases present in serum, and hence prevents non-selective release of the biologically active entity.
- the biological activity of the biologically active entity may be blocked or inhibited by several mechanisms, such as, for example, steric hindrance caused by the masking moiety-linking moiety assembly and/or masking of charged groups on the biologically active entity that are required for biological activity.
- Masking moieties suitable to prevent in vivo non-specific degradation of the linking moiety can range from chemical modification of the exposed terminus of the linking moiety, such as an amino or carboxy terminal modification, to small molecules such as drugs and genetically non-encoded amino acids or other enzymatically non-degradable amino acids (including, e.g., D-amino acids, .
- the masking moiety may be biologically inert, or it may itself have biological activity, such as any of the biologically active entities described infra or any other drug, even a drug with no cytotoxic or cytostatic activity.
- the biologically active entity is typically a molecule or construct that is cytotoxic and/or cytostatic to cells, but may be any agent or drug useful in the diagnosis and/or treatment of tumors and/or tumorigenic cancers.
- the types of molecules suitable for use as biologically active entities in the prodrugs of the invention can vary widely.
- the biologically active entity should comprise, or be modified to comprise, a reactive group capable of forming a covalent linkage with the appropriate terminus of the linking moiety. If the biologically active entity must be modified to effect linkage, it should be modified in a manner such that when it is selectively released it retains substantial biological activity.
- the biologically active entities can range from small organic compounds such as anthracyclines, doxorubicin, daunorubicin, folic acid derivatives, vinca alkaloids, calicheamycin, mitoxantrone, cytosine arabinosides, adenosine arabinosides, fludarabine phosphate, melphalan, bleomycin, mitomycin, L- canavanine, taxoids, camptothecin, proteasome inhibitor, famesyl transferase inhibitor, epothilone, discodermolide, maytansinoids, platinum derivatives, duocarmycins, combrestastatin and epipodophyllotoxins, to biological oligomers such as oligonucleotides, oligopeptides and oligosaccharides, to large biological polymers such as nucleic acids and polypeptides.
- small organic compounds such as anthracyclines, doxorubicin, daunorubicin,
- certain biologically active entities such as polypeptides
- the various linking moieties may be the same or different, and each linking moiety is in turn linked to a masking moiety, which may be the same or different for each linking moiety.
- the prodrugs of the invention may comprise one or a plurality of the same or different linking moieties.
- the biologically active entity may act intracellularly or extracellularly to exert its biological effect.
- the biologically active entity may be a small organic compound that is capable of traversing cell membranes and exerting its cytotoxic and/or cytostatic effects inside the cell (e.g., anthracyclines).
- the biologically active entity may be a molecule which binds an extracellular domain of a receptor and triggers cell death (e.g., cytokines such as TNF ⁇ ).
- the biologically active entity may also be an entity that acts intracellularly but that is either incapable of traversing the cell membrane or does not efficiently traverse the membrane on its own.
- Such intracellularly active biologically active agents may be coupled to a peptide that facilitates transport into the cell or cell nucleus. Selective delivery of a biologically active entity directly into the nucleus of a target cell may improve the selectivity of the biologically active entity and may overcome drug resistance to the biologically active entity.
- Intracellularly active agents that are not capable of traversing the cell membrane include intracellularly active polypeptides such as granzyme B, many antisense DNAs and RNAs, many ribozymes and genes useful for gene therapy.
- the masking moiety prevents the biologically active entity - transport peptide construct from entering cells prior to selective cleavage of the linking moiety.
- Prodrugs of the invention in which the biologically active entity includes a transport peptide permit selective delivery of biologically active entities to tumors and/or target cells that otherwise would be unable to selectively traverse the cell membrane or would do so with a low efficiency.
- the biologically active entity is an extracellularly active cytotoxic or cytostatic entity - i.e., an entity that inhibits the growth of and/or kills a cell without having to enter the cell.
- the extracellularly active cytotoxic or cytostatic entity may be virtually any molecule that can be linked to a masking moiety. Non-limiting examples include, e.g., peptides, lytic peptides, anti-angiogenic peptides and polypeptides.
- Preferred polypeptides are those that have a cytotoxic or cytostatic effect on tumor cells and include, but are not limited to, TNF ⁇ , IFN- ⁇ , IFN- ⁇ , IL-1 , IL-2, IL-6, IGF-1 antagonists, thrombospondin-1 derived peptides, substance P antagonists, TRAIL (Apo-2 ligand) and Fas ligand.
- Prodrugs of the invention including such extracellularly active biologically active entities permit selective delivery of the entities to target cells, thereby reducing their toxicity to the patient.
- the prodrugs of the invention are dual prodrugs - i.e., prodrugs in which both the masking moieties and biologically active moieties exert biological effect.
- the dual prodrugs comprise two intracellularly active entities.
- the dual prodrugs include prodrugs that selectively deliver two biologically active small molecules to target cells.
- Other dual prodrugs include prodrugs that deliver two molecules that act in concert against a target cell.
- dual prodrugs can deliver a polypeptide that interacts with an extracellular receptor and a small molecule that acts on an intracellular target.
- the dual prodrugs may comprise two drugs that are often prescribed in combination such as a cytotoxic agent and an antibiotic, or two drugs that act synergistically such as TNF ⁇ and doxorubicin or other combinations of biologically active compounds as are well known in the art.
- Preferred dual prodrugs are those that deliver two entities that act in concert against a target cell.
- the biologically active entity is a small organic intracellularly active compound capable of traversing the cell membrane, it is either included in the prodrug compositions of the invention in association with a transport peptide that acts to enhance its membrane permeation properties or as a dual prodrug in which the masking moiety also has some biological activity.
- Other biologically active entities such as the extracellularly active entities and other entities described supra may be included in the prodrugs of the invention with biologically inert masking moieties or as dual prodrugs in which the masking moiety also has some biological activity.
- the present invention provides pharmaceutical compositions comprising the prodrugs of the present invention.
- the pharmaceutical compositions generally comprise one or more prodrugs of the invention and a pharmaceutically acceptable carrier, excipient or diluent.
- the pharmaceutical compositions comprise an amount of prodrug that provides therapeutic benefit.
- the present invention provides methods of inhibiting the growth or proliferation of a tumor or a tumor cell or an endothelial cell involved in tumor neoangiogenesis.
- the method comprises contacting a tumor or a target cell with an amount of a prodrug or pharmaceutical composition of the invention effective to inhibit the growth or proliferation of the tumor cell or target cell.
- the method can be practiced to inhibit the growth or proliferation of tumors and/or target cells in vivo, in vitro or ex vivo.
- the present invention provides methods of treating solid tumors and their metastases and tumorigenic cancers.
- the method generally comprises administering to an animal, including a human, having a solid tumor and/or cancer an amount of a prodrug or pharmaceutical composition of the invention effective to halt the progression of tumor growth, thereby treating the animal.
- an amount of prodrug or pharmaceutical composition effective to shrink or eradicate the tumor is administered.
- FIG. 1 A illustrates an exemplary prodrug of the present invention
- FIG. 1 B illustrates a prodrug of FIG 1 A near a healthy cell
- FIG. 1 C illustrates the activation of the prodrug of FIG 1 A when near a tumor cell
- FIG. 2 illustrates the in vivo function of a prodrug of the present invention
- FIG. 3A illustrates the structure of two linking moieties of the present invention
- FIG. 3B illustrates the specific cleavage of a prodrug of one polarity in the extracellular milieu at or near a tumor or target cell
- FIG. 3C illustrates the specific cleavage of a prodrug of a second polarity in the extracellular milieu at or near a tumor or target cell
- FIG. 3D illustrates the specific cleavage of a prodrug comprising a spacing moiety
- FIG. 3E illustrates the specific cleavage of a dual polarity prodrug
- FIG. 4A illustrates a general scheme for the preparation of a prodrug of the present invention using protecting moieties
- FIG. 4B illustrates the preparation of a prodrug of the present invention
- FIG. 4C illustrates the preparation a prodrug comprising a spacing moiety
- FIG. 4D illustrates the preparation of a dual polarity prodrug
- genetically-encoded amino acid residues are generally designated with the three-letter abbreviations. Unless otherwise noted, the three-letter abbreviations designate L-enantiomers of the genetically encoded amino acids.
- Amino acids in the D-configuration will be explicitly labeled. For example, "Arg” designates L-arginine and "D-Arg” designates D-arginine.
- upper case letters designate amino acids in the L- configuration and lower case letters designate amino acids in the D-configuration.
- "R” designates L-arginine and "r” designates D-arginine.
- Bioly active entity refers to a molecule or construct that exerts a biological effect on a target cell, as defined herein.
- the entity is cytotoxic and/or cytostatic toward target cells or sensitizes target cells to the action of another cytotoxic or cytostatic entity.
- Linking moiety refers to a molecular moiety with a structure as described herein that links a biologically active entity to a masking moiety and that is susceptible to specific, selective cleavage at or near a tumor or a target cell, as defined herein.
- Normal cells refer to cells and/or tissues that are not involved in tumor formation, growth and metastasis.
- endothelial cells involved in tumor neoangiogenesis are not included in the definition of normal or healthy cells.
- “Masking moiety” refers to a molecular moiety that, when linked to a biologically active entity via a linking moiety, is capable, together with the linking moiety, of masking the biological activity of the entity and is capable of preventing the non-specific degradation of the linking moiety.
- Polypeptide refers to a polymer of two or more amino acids. The term also includes mimics of polymers of amino acids known to those of skill in the art (e.g. peptidomimetics) and derivatives of polymers of amino acids (e.g., glycopeptides).
- peptide refers to a polypeptide having from about 2 to about 40 to 50 amino acids.
- Specific cleavage refers to cleavage that is sequence dependent. Thus, specific cleavage of a linking moiety is cleavage that occurs as the result of a peptidase recognizing and cleaving the particular amino acid sequence of the linking moiety.
- Specific cleavage is therefore a property of the amino acid sequence of the linking moiety and is to be distinguished from cleavage and/or degradation caused by non-specific means, such as non-specific degradation by exopeptidases present in the serum or gut.
- Selective cleavage refers to the enhanced or preferential specific cleavage achieved at or near a target cell.
- specific cleavage of the linking moiety is not unique to target cells, the greater cleavage achieved at or near target cells renders the cleavage "selective" for purposes of the present invention.
- Target cell refers to a tumor cell or to an endothelial cell involved in tumor neoangiogenesis.
- the present invention provides novel prodrugs comprising a biologically active entity linked to a masking moiety via a linking moiety.
- the prodrugs of the present invention are generally compounds according to formula (I):
- M is a masking moiety
- L 1 is a linking moiety
- B is a biologically active entity
- n is a positive integer from 1 up to the total number of reactive groups in the biologically active entity.
- the masking moiety prevents the non-specific degradation of the linking moiety and (M - L 1 ) n masks the biological activity of the biologically active entity, rendering it inactive until specifically released.
- the linking moiety is susceptible to specific, selective cleavage at or near a tumor or target cell.
- the linking moiety can comprise any molecule that is susceptible to specific cleavage at or near a tumor or a target cell.
- the linking moiety is covalently linked to the masking moiety and to the biologically active entity, thereby linking the two together.
- tumors and target cells secrete into the extracellular medium a factor or factors such as proteases or peptidases that are capable of specifically cleaving the linking moiety.
- endothelial cells involved in tumor neoangiogenesis display the same secretory activity. While healthy cells also produce a factor or factors that specifically cleave the linking moiety, tumor cells and endothelial cells involved in tumor neoangiogenesis excrete a significantly higher concentration of the factor thereby permitting specific and selective cleavage at or near tumors and/or target cells.
- FIG. 1 The resulting improved selectivity of action of the biologically active entity is illustrated in FIG. 1.
- FIG. 1A illustrates an exemplary prodrug 8 of the present invention comprising a masking moiety 10 linked to a biologically active entity 12 via a linking moiety 14.
- prodrug 8 is not active near healthy cell 16 because masking moiety 10, alone or in combination with linking moiety 14, masks the biological activity of biologically active entity 12 and linking moiety 14 is relatively stable at or near healthy cell 16.
- target (tumor or angiogenic endothelial) cell 18 secretes a factor 20 which is capable of specifically cleaving the linkage between linking moiety 14, liberating released biologically active entity 12'.
- Liberated biologically active entity 12' is free to exert its activity on target cell 18.
- biologically active entity 12' might bind receptor 22 on the surface of target cell 18, thereby initiating an intracellular cascade leading to the apoptosis or another form of death of tumor cell 18. Because normal cell 16 does not secrete factor 20, or secretes very little factor 20, prodrug 8 remains intact near normal cell 16. Thus, biologically active entity 12 is not active near normal cell 16. As illustrated in FIG. 2, formulation of the biologically active entity as a prodrug can reduce the toxicity of the biologically active entity.
- Factor 20 can be any molecule or condition in the environment at or near target cell 18 that is capable of specifically cleaving linking moiety 14. While not intending to be bound by theory, it is believed that factor 20 is a protease or peptidase selectively secreted by target cells. However, since all proteases or peptidases that specifically cleave the linking moiety have not yet been identified, factor 20 can be any condition that is capable of specifically cleaving the linking moiety. For instance, factor 20 might even be low pH conditions near a target cell. Factor 20 is selectively present at or near target cells.
- prodrug 8 can be present at or near target cells exclusively, or it can be enriched at or near target cells such that prodrug 8 is cleaved preferentially at or near target cells and administration of prodrug 8 displays improved selectivity for target cells relative to administration of the naked biologically active entity 12 or released biologically active entity 12'.
- Preferred peptide linking moieties comprise the amino acid sequence Ala-Leu-Ala-Leu (SEQ ID NO:1 ), Leu-Ala-Leu-Ala-Leu (SEQ ID NO:2), Leu-Ala-Leu (SEQ ID NO:3), Leu-Ala (SEQ ID NO:4) or Leu-Ala-Phe
- linking moiety is specifically cleaved at two sites.
- a first protease or peptidase is believed to cleave the first amide bond of each Leu-Ala-Leu sequence of the linking moiety (i.e. the amide bond between the N-terminal Leu and the Ala in the sequence), as illustrated by solid arrows in FIG. 3A.
- iBu represents isobutyl
- Me represents methyl
- Ph represent phenyl and x and y are as previously defined above.
- a second protease or peptidase is believed to subsequently cleave the amide bond of the Ala-Leu or Ala-Phe residues of the linking moiety, as indicated by dashed lines in FIG. 3A.
- specific cleavage may also occur at other amide bonds or at other bonds within the linking moiety.
- the linking moiety is covalently linked to the biologically active entity via one terminus and to the masking moiety via the other terminus.
- the "polarity" of the linkages i.e., whether the N-terminus of the linking moiety is linked to the biologically active entity or to the masking moiety, may or may not be critical, and will depend upon the identities of the biologically active entity and masking moiety.
- linking moiety 30 The different possible polarities of the linkage and the resultant specific cleavage products are illustrated in FIG. 3B and FIG. 3C with linking moiety 30.
- masking moiety M is linked to the amino terminus of linking moiety 30 and biologically active entity B is linked to the carboxy terminus of linking moiety 30.
- both linkages are amide linkages, although other stable linkages could also be used, as will be described in more detail in a later section.
- the first protease or peptidase is believed to cleave the amide bonds between the first Leu and the Ala of the Leu-Ala-Leu sequences of the linking moiety thereby liberating released masking moiety 35.
- a second protease or peptidase cleaves the N-terminal Ala residue from the amino terminus of the derivative of the biologically active entity thereby liberating released biologically active entity 39.
- linking moiety is a peptide with the amino acid sequence of Leu-Ala-Leu-Ala-Leu
- cleavage of the linking moiety is believed to liberate a Leu derivative 35 of the masking moiety and a Leu derivative of the biologically active entity 39.
- the Leu derivative of the masking moiety 35 has a free carboxy terminus
- the Leu derivative of the biologically active entity has a free amino terminus.
- a prodrug 46 according to the invention including a spacing moiety is specifically cleaved to yield released masking moiety 35 and released biologically active entity 48.
- a spacing moiety illustrated in this example as 6-aminocaproic acid
- amide linkages are illustrated, other stable linkages could be used, as will be described in more detail in a later section.
- the spacing moiety can be long or short, rigid, semi-rigid or flexible, hydrophobic or hydrophilic, depending upon the particular application.
- the spacing moiety may be any molecule having reactive groups capable of forming covalent linkages with the linking moiety and the biologically active entity and/or masking moiety. Reactive groups that are capable of forming suitable linkages with the amino and carboxy termini of linking moieties are described in more detail below in connection with the biologically active entity and masking moiety.
- Molecules suitable for use as spacing moieties include, but are not limited to, peptides such as polyglycine (flexible) or polyproline (rigid), aminoalkylcarboxylic acids (e.g., 4-aminobutanoic acid, 5-aminopentanoic acid, 6- aminocaproic acid, etc.), polyaikyiene oxides such as polyethylene glycol and others as will be apparent to those of skill in the art.
- the spacing moiety should preferably be a molecule which is biologically inert i.e., a molecule that does not elicit an immunological response or other adverse or toxic response and should not significantly adversely affect the biological activity of released biologically active entity 48.
- the spacing moiety may be used to link two peptide sequences that are specifically cleavable, as illustrated in
- dual prodrug 52 comprises two biologically active entities 38 linked together via dual polarity linking moiety 58.
- Dual polarity linking moiety 58 comprises two specifically cleavable peptides 53 and 57, which themselves may constitute linking moieties as discussed above, linked together via spacer moiety 55.
- Spacer 55 is a dicarboxylic acid that is linked to the amino termini of both peptides 53 and
- linking moiety 58 has two carboxy termini. Specific cleavage of dual prodrug 52 yields released biologically active entities 39 and short peptide derivatives of linking moiety 58.
- Optional spacing moieties could be included between the linking moiety 58 and one or both biologically active entities 39, as previously described.
- all the linking moieties of the prodrug may be the same, some of the linking moieties may be the same and others different, or each linking moiety may be different.
- all or some of the masking moieties can be the same, or they can be different.
- one, some, all or none of the linking moieties may include spacing moieties and when included, the various spacing moieties may be the same or different.
- the masking moiety prevents the non-specific cleavage and/or degradation of the linking moiety and, alone or together with said linking moiety, inhibits the biological effects of the biologically active entity. It may also, as will be discussed in more detail below, provide the prodrug composition with additional favorable properties such as longer in vivo half-life, increased stability, higher solubility, etc.
- Preferred masking moieties are those that are stable in vivo, nontoxic to healthy cells and non- immunogenic.
- the masking moiety may comprise a chemical modification of the exposed terminus of the linking moiety that prevents the linking moiety from being non-specifically cleaved or degraded in vivo, such as, for example by non-specific exopeptidases that may non-specifically degrade the linking moiety in vivo and prematurely release the biologically active entity.
- the exposed terminus of the linking moiety is the amino terminus
- amino terminal acetylation of the linking moiety may provide sufficient resistance to degradation to serve as a masking moiety.
- carboxy terminal modification, such as amidation or esterification, of the linking moiety may similarly provide sufficient resistance to degradation.
- Other chemical modifications that inhibit or prevent non-specific degradation and/or cleavage will be apparent to those of skill in the art.
- the masking moiety may also comprise one or more genetically non-encoded amino acid.
- the masking moiety can be a peptide consisting of one or more D-amino acids, one or more ⁇ -amino acids or mixtures of D- and ⁇ -amino acids.
- Preferred masking groups according to this class include N-methyl- alanine ("Me-Ala"), D-alanine and ⁇ -alanine.
- masking moieties can comprise biologically inert molecules.
- molecules include small molecules such as dyes and polymers such as biological and non-biological polymers.
- polyaikyiene glycols such as polyethylene glycol can prevent the degradation of a linking moiety and inhibit the activity of a biologically active entity.
- Preferred polyethylene glycol masking moieties have average molecular weights of about 1000 Da, about 4000 Da, about 5000 Da, about 8000 Da, about 10000 Da or about 12000 Da.
- Other suitable biological and non-biological polymers include, but are not limited to copolymers of divinyl ether and maleic anhydride (DIVEMA) or 2- hydroxypropyl methacrylate (HPMA), and other polymers such as DNA and carbohydrates.
- DIVEMA divinyl ether and maleic anhydride
- HPMA 2- hydroxypropyl methacrylate
- the masking moiety can also be a polypeptide that prevents the degradation of the prodrug and inhibits or prevents the activity of the biologically active entity.
- Preferred polypeptide masking moieties are non-immunogenic polypeptides.
- suitable polypeptide masking moieties include albumin, immunoglobulins, or an antibody.
- the masking moiety itself can have biological activity or other therapeutic activity.
- Prodrug compounds wherein the masking moiety has activity (“dual prodrugs") are described in detail below.
- Suitable active masking moieties include cytostatic and cytotoxic small molecules, other therapeutically active small molecules, therapeutically active polypeptides and other therapeutically active molecules known to those of skill in the art.
- the masking moiety should either include a reactive group that is complementary to the terminus of the linking moiety to which it will be linked or be modified to include such a group.
- the masking moiety should include a reactive group that is capable of forming a covalent linkage with the amino terminus, such as a carboxyl group.
- the linkage formed should be stable to the conditions of use of the prodrug, e.g., in the serum.
- Complementary reactive groups that are capable of reacting with the carboxy and amino termini of peptides to form stable linkages that may be included in the masking moiety are described in more detail below in connection with the biologically active entities.
- the masking moiety may inherently include such a complementary reactive group, or may be modified to include a suitable complementary reactive group. The methods of modification will depend upon the identity of the masking moiety and will be apparent to those of skill in the art.
- the biologically active entity can be any entity that has biological activity against tumors or target cells, or any entity that would derive an advantage from being selectively administered to a tumor or target cell.
- Preferred biologically active entities include those entities that are cytotoxic and/or cytostatic to tumors and/or target cells such as, for example TNF ⁇ , IFN- ⁇ , IFN- ⁇ , IL-1 , IL-2, IL-6, an IGF-1 antagonist, a lytic peptide, an antiangiogenic peptide, a thrombospondin-derived peptide, a substance P antagonist, TRAIL (Apo-2 ligand) and Fas ligand, and also constructs comprising intracellularly active agents and a transport peptide allowing or facilitating their uptake in cells.
- the biologically active entity in order to be formulated as a prodrug of the invention, the biologically active entity must either inherently include, or be modified to include, a reactive group which is complementary to, i.e., able to react to form a covalent linkage with, the reactive group on the linking moiety to which it will be covalently attached.
- a reactive group which is complementary to, i.e., able to react to form a covalent linkage with, the reactive group on the linking moiety to which it will be covalently attached.
- pairs of such complementary reactive groups include nucleophile/electrophile pairs, as are well known in the art.
- the biologically active entity will be covalently attached to the
- Suitable reactive groups complementary to the linking moiety amino terminus include, for example, carboxy groups, esters (including activated esters such as NHS-esters), acyl azides, acyl halides, acyl nitriles, aldehydes, alkyl sulfonyl halides, halotriazines, imidoesters, isocyanates, isothiocyanates, sulfonate esters, etc.
- Suitable reactive groups complementary to the linking moiety carboxy terminus include, for example, amines, alcohols, alkyl halides, thiols, hydrazines, diazoalkanes, sulfonate esters, etc.
- the linkage between the linking moiety and the biologically active entity is an amide.
- Conditions for linking molecules together having complementary amino and carboxy groups to form amide linkages are well-known (see, e.g., Merrifield, 1997, Methods Enzymol. 289:3-13). Specific linking chemistries are provided in the Examples section.
- the preferred linkage is an amide bond between the carboxy terminal amino acid residue of the linking moiety and a free amino group of the polypeptide.
- the free amino group can be, for instance, at the amino terminus of the polypeptide or at the side chain of an amino acid, e.g. a lysine residue.
- a plurality of linking moieties may be linked to a single biologically active polypeptide molecule.
- the molar ratio of linked linking moieties can be conveniently controlled by adjusting the biologically active entity:linking moiety molar ratio of the conjugation reaction. Specific cleavage of the linking moiety in the vicinity of target cells such as tumor cells releases the biologically active polypeptide modified with a leucine residue or a phenylalanine residue at each amine group from which a linking moiety is cleaved.
- the linking moiety can be linked to any other reactive group of the biologically active entity.
- the linking moiety can be linked to a free carboxyl group of the biologically active entity at, for example, the carboxy terminus or at the side chain of an acidic amino acid of a polypeptide or at a free carboxy group of other entities.
- the linking moiety can also be linked to other reactive moieties in the polypeptide including sulfhydryl moieties and other moieties known to those of skill in the art that are capable of forming a bond to the linking group.
- Appropriate adaptor moieties for each reactive moiety will be apparent to those of skill in the art.
- a biologically active entity may include a reactive group that does not yield a suitably stable linkage with the linking moiety, or it includes a reactive group that is not complementary to the desired reactive group on the linking moiety.
- both the biologically active entity and the desired point of attachment to the linking moiety may include carboxyl groups.
- the reactive group on either the biologically active entity or the linking moiety may first be converted to a complementary reactive group through the use of a bifunctional adaptor molecule.
- a suitable bifunctional adaptor molecule for linking a biologically active entity including a carboxyl group to the carboxy terminus of a linking moiety could be a diamino alkyl, such as 1 ,3 diamino propane.
- adaptor molecules are somewhat analogous to the previously described spacer moieties used to construct dual polarity linking moieties of the invention (illustrated in FIG. 3E). Molecules suitable for use as adaptor molecules will depend upon the identities of the reactive groups, and will be apparent to those of skill in the art.
- the biologically active entity is linked to the linking moiety via those reactive groups of the biologically active entity on which the biologically active entity can tolerate derivatization without significant loss of biological activity.
- the prodrugs typically liberate a leucyl derivative of the biologically active entity upon specific cleavage of the linking moiety, the liberated leucyl derivative of the biologically active entity should possess optimal activity.
- leucyl derivatives of the biologically active entity can be prepared and assayed for functional activity in, for instance, cell-based assays such as those described in the examples below and other assays suitable for measuring the activity of the biologically active entity known to those of skill in the art.
- the leucyl derivative of the modified biologically active entity is assayed for optimal activity.
- the prodrug itself is also assayed for optimal activity.
- the intact prodrug should possess little or no activity in a normal physiological environment while the activated, released biologically active entity should possess optimal activity.
- Assays for functional activity include those assays known to those of skill in the art for measuring the stability, activation, toxicity and therapeutic activity of the prodrug. The assays can be conducted in vivo using, for instance test animals, or in vitro using cell based assays known to those of skill in the art.
- Preferred assays include cell-based assays using tumor cell models known to those of skill in the art. Exemplary assays for the stability, activation, toxicity and therapeutic activity are presented in the examples below.
- a number of prodrugs can be prepared by varying the ratio of masking/linking moiety and biologically active entity.
- the prodrug is prepared by solid phase or solution phase techniques the site of attachment of the masking/linking moiety to the biologically active entity can also be controlled.
- the results of activity assays for leucyl derivatives of the biologically active entity, described above, can be used to determine potentially useful stoichiometries and/or sites of attachment prior to screening.
- Ideal prodrugs are those that display the optimal combination of stability, toxicity, activation and therapeutic activity according to assays suitable for the biologically active entity known to those of skill in the art.
- the biologically active entity of the prodrug is an extracellularly active biologically active entity.
- An extracellularly active biologically active entity is an entity that can exert its biological activity without having to enter a cell.
- Preferred extracellularly active biologically active entities are those molecules that cannot traverse the cell membrane by themselves.
- Extracellularly active biologically active entities include small molecules such as small molecule agonists and antagonists of extracellular receptors and other small molecules that act extracellularly.
- Extracellularly active biologically active entities also include peptides and polypeptides such as cytokines, peptidic hormones, antibodies, and other extracellularly active molecules known to those of skill in the art.
- a prodrug selectively delivers active TNF ⁇ to target cells.
- TNF ⁇ can be linked to a masking moiety via any linking moiety of the present invention.
- TNF ⁇ is produced by many different cell types as a 26kDa (233 amino acids) integral transmembrane protein from which a 17 kDa (157 amino acids) mature TNF ⁇ is released into the extracellular medium by proteolytic cleavage of an Ala-Val bond between residues 76-77. Its potential use as an antitumor entity led to its purification, cloning and expression as a recombinant protein.
- Biologically active TNF ⁇ exists as a trimer in solution and each subunit is a polypeptide of 157 amino acids. Each mature TNF ⁇ trimer can interact with three receptor molecules at the interface of the subunits.
- TNF ⁇ mediates its activities by binding to specific receptors on the surface of the majority of mammalian cells. Receptor aggregation upon TNF ⁇ binding might be the mechanism for receptor activation in the target cells (Banner et al., 1993, Cell 73:431 -445). For an extensive review on TNF ⁇ , see Sidhu and Bollon, 1993, Pharmacol. Ther. 57:79-128.
- TNF ⁇ can be cytotoxic, and cytostatic, on many cell types in vitro. However, this antiproliferative effect is not restricted to tumor cells and many normal cells, such as endothelial cells, smooth muscle cells, adipocytes, fibroblasts and keratinocytes are also inhibited by TNF ⁇ . Sensitivity of human endothelial cells to TNF ⁇ is correlated with their rate of proliferation.
- phase I and II Multiple clinical studies (phase I and II) have been carried out with recombinant TNF ⁇ as an anticancer entity without major therapeutic effect.
- TNF ⁇ resistance and mainly TNF ⁇ -induced systemic toxicity are two major limitations for the use of TNF ⁇ as an antineoplastic entity.
- TNF ⁇ can be used in clinical trials only if injected locally or by isolated limb perfusion owing to the severe toxicity after systemic injection.
- Data from phase I clinical studies, in which TNF ⁇ was administered in a variety of schedules have shown that the common toxic side effects include fever, chills, rigor, fatigue, diarrhea, nausea, headache, and hypotension. Severe hypotension is the dose-limiting toxicity. No significant clinical antitumor effects were observed in phase II trials when TNF ⁇ was given as a single entity.
- TNF ⁇ showed promise in the regression of tumors in mice
- the toxicity of TNF ⁇ prevents therapeutic effect in humans.
- Tumor regression in mice requires a dose of approximately 400 ⁇ g/kg while humans can tolerate only 8 to 10 ⁇ g/kg before life threatening toxicities set in (Kramer, et al., 1988, Cancer Research 48:920-925).
- TNF ⁇ has a very short half-life of 20 minutes after injection into humans. TNF ⁇ is rapidly cleared from blood and taken up by the kidney and the liver. It is moreover sensitive to N-terminal endopeptidases that inactivate it rapidly ( ⁇ akamura and Komiya, 1996, Biol. Pharm. Bull. 19:677-677).
- TNF ⁇ can be conjugated to gelatin using carbodiimide. It retains 57% of its cytotoxic activity and is more active against tumors in vivo (Tabata et al., 1993, J. Pharm. Pharmacol. 45:303-308). TNF ⁇ was also coupled to polyethylene glycol via an amide bond between a lysine amino residue of TNF ⁇ and a terminal succinate group of PEG (N-succinimidyl succinate monomethoxy polyethylene glycol of a molecular weight of 5000).
- TNF ⁇ has also been conjugated to a divinyl ether and maleic anhydride copolymer (DIVEMA) of a molecular weight of 30.000.
- DIVEMA divinyl ether and maleic anhydride copolymer
- TNF ⁇ was covalently coupled to PEG polymers and separated into fractions of various molecular sizes (Tsutsumi et al., 1995, supra). Increasing amounts of PEG relative to TNF ⁇ significantly reduced the specific activity of the TNF ⁇ (Tsutsumi et al., 1995, supra). However, the PEG conjugates displayed improved pharmacokinetic stability when compared to native PEG (Tsutsumi et al., 1995, supra).
- the PEG-TNF ⁇ conjugates showed greater tumor distribution in vivo than native TNF ⁇ (Tsutsumi et al., 1995, supra).
- the most effective PEG-TNF ⁇ conjugate which had 56% of its lysine amino residues coupled to PEG, showed a 100- fold improved antitumor potency in vivo when compared to native PEG despite a 2-fold reduction in specific activity (Tsutsumi et al., 1995, supra).
- This derivative has also very striking activity against TNF ⁇ resistant tumors (Tsutsumi et al., 1995b, British J. of Cancer
- TNF ⁇ can be formulated as a prodrug according to the present invention.
- a TNF ⁇ prodrug should display comparable plasma stability and tissue distribution to the PEG-TNF ⁇ conjugates described above.
- the prodrug conjugates should display little or no loss of TNF ⁇ specific activity in vivo.
- the prodrug can carry as much PEG as necessary to achieve complete inactivation, ensuring reduced toxicity and allowing the use of higher dose levels.
- TNF ⁇ is formulated as a prodrug in which the masking moiety is a biocompatible polymer such as a polyaikyiene glycol, preferably polyethylene glycol (PEG).
- PEG molecules of various average molecular weights can be used such as 1000 Da, 4000 Da, 5000 Da, 8000 Da, 10000 Da, 120000 Da or even higher.
- the linking moiety can be any linking moiety according to the present invention.
- Preferred linking moieties include Ala-Leu-Ala-Leu (SEQ ID NO:1 ), Leu-Ala-Leu-Ala-Leu (SEQ ID NO:2), Leu-Ala-Leu (SEQ ID NO:3), Leu-Ala (SEQ ID NO:
- TNF ⁇ includes several free amino groups, multiple different masking moieties and linking moieties can be used simultaneously.
- the degree to which the free amino groups of the TNF ⁇ are saturated with PEG- masked linking moieties will depend upon, among other factors, the average molecular weight (MW) of the PEG (or other masking polymer). Generally, the higher the MW of the polymer or PEG, the lower the degree of saturation that is required to inactivate the activity of the TNF ⁇ in the prodrug formulations. Specific levels of saturation for a variety of PEGs of varying MWs are taught in Tsutsumi et al., 1995, supra.
- TNF ⁇ prodrugs of the invention is the ability to use a considerably higher level of saturation than that reported by Tsutsumi et al., 1995, supra.
- the PEG or polymer masking moieties are specifically and selectively cleaved at or near a tumor or target cell, when formulated as a prodrug according to the invention, the TNF ⁇ can be completely inactivated by the PEG or polymer masked linking moieties.
- the TNF ⁇ molecule may be saturated with PEG-masked linking moieties.
- the PEG-TNF ⁇ prodrugs of the invention in addition to being selective, may exhibit even lower toxicities than the PEG-TNF ⁇ complexes described in the art.
- Specific PEG-TNF ⁇ prodrugs of the invention, as well as methods for their synthesis, are provided in the Examples.
- a prodrug selectively delivers an oligopeptide antagonist of insulin-like growth factor (IGF-1 ) to tumors or target cells in vivo.
- the masking moiety can be selected from any of the masking moieties discussed above, and the linking moiety can also be selected from any of the linking moieties discussed above.
- the masking moiety is a polymer such as PEG, more preferably a succinylated derivative of PEG, and the linking moiety is the tetrapeptide Ala-Leu-Ala-Leu.
- the linking moiety is linked to free amino groups of the antagonist, either at one or more lysine side chains and/or at the amino terminus.
- insulin-like growth factors and their type I receptor are very often up-regulated during the development of many cancer types. Recent data show that, besides stimulating cell transformation and tumor cell cycle progression, signaling through the IGF-1 receptor exerts an important tumor promotion effect by inhibiting tumor cell apoptosis (including drug-induced apoptosis). Consistently, inhibition of the IGF-mediated survival function is likely to increase the antitumor effects of conventional chemotherapy (Gooch J.L. et al., 1999, Breast Cancer Res. Treat. 56:1 -10).
- Antagonists of IGF-1 composed wholly of D-amino acids have been designed which resemble IGF-1 receptor ligands and efficiently inhibit IGF-1 receptor function in vitro and in vivo.
- One such peptide is D-Cys-D-Ser-D-Lys-D-Ala-D-Pro-D-Lys-D-Leu-D- Pro-D-Ala-D-Ala-D-Tyr-D-Cys which is a retro-enantio sequence derived from the D domain of IGF-1 .
- Such antagonists could become very useful anticancer entities, but because of the crucial importance of IGF-1 receptor-mediated signaling in many normal cells and tissues, as well as the high similarity between the IGF-1 receptor and the insulin receptor, such antagonists must be administered selectively to cancer cells to avoid toxic side effects.
- PEG is linked to the IGF-1 antagonist via the tetrapeptide linker Ala-Leu-Ala-Leu.
- the antagonist is derivatized only on those reactive groups that can be derivatized with leucine without significant loss of antagonist activity.
- a prodrug compound is capable of selectively delivering to target cells an antiangiogenic peptide derived from the structure of the angiogenesis inhibitor thrombospondin-1 (TSP-1).
- TSP-1 angiogenesis inhibitor thrombospondin-1
- Thrombospondin-1 is a naturally occurring inhibitor of angiogenesis and provides one source for the development of new anti-angiogenic molecules.
- TSP-1 is a 450-kDa homotrimeric protein with multiple structural domains that contribute to its involvement in diverse biological activities including angiogenesis.
- the therapeutic potential of TSP-1 has been demonstrated in animal models where it has been shown to block the growth and progression of malignant tumors by hindering neovascularization.
- peptides derived from the primary sequence of TSP-1 are formulated as prodrug compounds for selective delivery to target cells.
- peptide sequences that comprise reverse sequences of D-amino acids derived from a type-l repeat of amino acids from the primary structure of TSP-1 have antiproliferative and antiangiogenic properties (Dawson et al., 1999, supra). Such peptides are preferred for formulation as prodrug compounds in this embodiment of the invention.
- preferred masking moieties include biocompatible polymers such as PEG
- preferred linking moieties include Ala-Leu-Ala- Leu (SEQ ID NO:1 ), Leu-Ala-Leu-Ala-Leu (SEQ ID NO:2), Leu-Ala-Leu (SEQ ID NO:3), Leu-Ala (SEQ ID NO:4) or Leu-Ala-Phe (SEQ ID NO:5).
- substance P antagonists are formulated as prodrug compounds for selective delivery to target cells.
- substance P antagonists are formulated as prodrugs for selective delivery to target cells.
- a preferred substance P antagonist is a peptide with the amino acid sequence D-Arg-Pro-Lys-Pro-D-Trp-Gln-D-Trp-Phe-D-Trp- Leu-Leu-NH 2 ("SPD").
- Preferred masking moieties include biocompatible polymers such as PEG, and preferred linking moieties include Ala-Leu-Ala-Leu (SEQ ID NO:1 ), Leu-Ala- Leu-Ala-Leu (SEQ ID NO:2), Leu-Ala-Leu (SEQ ID NO:3), Leu-Ala (SEQ ID NO:4) or Leu- Ala-Phe (SEQ ID NO:5).
- preferred linking moieties include Ala-Leu-Ala-Leu (SEQ ID NO:1 ), Leu-Ala- Leu-Ala-Leu (SEQ ID NO:2), Leu-Ala-Leu (SEQ ID NO:3), Leu-Ala (SEQ ID NO:4) or Leu- Ala-Phe (SEQ ID NO:5).
- the biologically active entity can be a polypeptide. Any cytotoxic and/or cytostatic polypeptide can be formulated as a prodrug according to the present invention.
- preferred linking moieties include peptides and the preferred linkage between the polypeptide biologically active entity and the linking moiety is an amide bond.
- Suitable polypeptides include the extracellularly active polypeptides described above including TNF ⁇ , IFN- ⁇ , IFN- ⁇ , IL-1 , IL-2, IL-6, an IGF-1 antagonist, thrombospondin-1 derived peptides, a substance P antagonist, TRAIL (Apo-2 ligand) and Fas ligand.
- Polypeptides suitable for these embodiments of the invention also include polypeptides that are not necessarily extracellularly active.
- Polypeptide biologically active entities include intracellularly active polypeptides such as, for example, granzyme B and other polypeptides with diverse functions such as, for example, Iytic peptides.
- a prodrug selectively delivers to target cells a peptide that is capable of lysing those cells in vivo.
- a Iytic peptide is linked to any of the masking moieties discussed supra via any of the linking moieties discussed supra.
- the linking moieties can be linked to any reactive group of the
- Iytic peptide such as free amino groups.
- Preferred masking moieties include PEG and preferred linking moieties include the tetrapeptide Ala-Leu-Ala-Leu.
- a succinylated PEG derivative can conveniently be linked to the linking moiety.
- Melittin a 26-residue peptide found in the venom of the European honey bee is cytolytic. Its activity is dependent on the amphipathicity of the alpha-helix formed by its first 20 amino acids (Dempsey, 1990, Biochim. Biophys. Acta 1031 :143-161 ; Werkmeister et al., 1993, Biochim. Biophys. Acta 1157:50-54, 1993). On the basis of the amphipathic alpha-helical structure of melittin, simpler sequences have been designed that have similar or greater cytolytic activity (Cornut et al., 1994, FEBS Lett. 349:29-33; Castano et al., 1999, Biochim.
- a similar sequence made of D-lysine and D-leucine residues forms an amphipathic alpha-helix with similar cytolytic properties. It has the advantage of resistance to the action of most mammalian peptidases found in body fluids, and is therefore much more stable in vivo.
- the action of the Iytic peptide on tumor cell membranes could overcome drug resistance directly (lysis), by enabling a cytotoxic drug to enter cells to a greater extent, or by disrupting metabolic processes involved in the resistance mechanism.
- Iytic peptides active on mammalian cells Due to their intrinsic cytolytic activity, naked Iytic peptides active on mammalian cells are inherently toxic. They must be targeted specifically to tumor cells in the form of prodrugs.
- the prodrug comprises the Iytic peptide LK15 linked to the masking moiety PEG via the tetrapeptide linking moiety Ala-Leu-Ala-Leu.
- the Iytic peptide is derivatized only on those reactive groups that can tolerate leucyl-derivatization without significant loss of Iytic activity.
- the biologically active entity is a construct comprising an intracellularly active entity linked to a transport peptide.
- the intracellularly active entity is cytotoxic or cytostatic toward cells and exerts its cytotoxic or cytostatic activity within the cell.
- Prodrug compounds comprising intracellularly active entities are illustrated by Formula (II):
- Suitable intracellularly active entities include intracellularly active small molecules, peptides, proteins, nucleic acids or analogs thereof. These entities may or may not be able to penetrate the cells by themselves.
- suitable intracellularly active entities include small molecules capable of penetrating cells such as anthracyclines, doxorubicin, daunorubicin, folic acid derivatives, vinca alkaloids, calicheamycin, mitoxantrone, cytosine arabinoside, adenosine arabinoside, fludarabine phosphate, melphalan, bleomycin, mitomycin, L-canavanine, taxoids, camptothecins, proteasome inhibitors, farnesyl-protein transferase inhibitors, epothilones, maytansinoids, discodermolide, platinum derivatives, duocarmycins, combretastatin and epipodophyllotoxins.
- Intracellularly active entities also include larger molecules that are unable to penetrate cells or inefficiently penetrate cells such as antisense nucleic acids including antisense RNA and DNA, ribozymes, DNA, cDNA, genes, proteins and polypeptides.
- the transport peptide portion of the construct enables, facilitates or enhances transport of the intracellularly active entity into the target cell and/or nuclear translocation of the entity.
- the action of any biologically active entity, including intracellularly active biologically active entities can potentially be improved by formulation as a prodrug with a transport peptide construct.
- formulation of an intracellularly active biologically active entity, such as doxorubicin, as a prodrug with a transport peptide construct may not only improve the uptake of the entity, it may also allow delivery of the entity to the nucleus of the cell. Improved nuclear delivery of the entity that is active in the nucleus would increase its efficiency of action and would allow reduced resistance to the entity.
- peptides Four distinct types have been recently characterized that have the unusual property of being transported into the cell and/or into the nucleus, and to carry with them, complexed or conjugated peptides, proteins, nucleic acids, as well as small molecules.
- the Antennapedia peptide is a 16-amino acid polypeptide (Lys-Lys-Trp-Lys-Met- Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg-Gly) corresponding to the third helix of the DNA-binding homeodomain of Antennapedia, a Drosophila transcription factor (Derossi et al., 1994, J. Biol. Chem. 269:10444-10450).
- the translocation process seems to be based on the establishment of direct interactions between the positively charged peptide and the negatively charged membrane phospholipids followed by the induction of inverted micelles.
- the hydrophilic cavity of the micelles accommodates the peptide that can subsequently be released in the cytoplasmic compartment (Derossi et al., 1996, supra).
- This peptide has been used in vitro to carry intracellularly into cancer cells a CDK inhibitor and a p53-derived peptide (Bonfanti et al., 1997, Cancer Res. 57:1442-1446; Kim et al., 1999, J. Biol. Chem. 274:34924-34931 ).
- Tat is a 86-amino acid protein involved in the replication of HIV-1. Exogenous Tat protein translocates through the plasma membrane and reaches the cell nucleus. This translocation activity has been assigned to a cluster of basic amino acids, and short peptides including this cluster can translocate through the plasma membrane as well, and convey proteins to the nucleus.
- One example of such a short and very effective peptide is Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Arg-Pro-Pro-Gln-Cys. Translocation also occurs at 4°C and does not involve endocytosis or recognition by a membrane receptor. The mode of translocation seems to be similar to that of the Antennapedia peptide and involves the interaction of the basic amino acids with the negatively charged phospholipids of the cell membrane (Vives et al., 1997, supra).
- Polypeptides consisting of 6 to 25 residues, at least 50% of which contain a guanidino or an amino moiety, are also able to translocate across cell membranes compounds such as small organic molecules, peptides, proteins and nucleic acids at 4°C as well as at physiological temperature. Particularly, peptides consisting of 9 contiguous arginine residues were shown to very efficiently translocate into every cell type tested antisense peptide nucleic acids, ovalbumin, antibodies, diverse peptides, cyclosporin and taxol. The precise mechanism of translocation is still unknown (PCT Application No.
- the fourth class of peptides are derived from the CDR regions of polyreactive anti-DNA antibodies occurring naturally or pathologically in mice and humans.
- An example of a 30 amino acid transport peptide derived from an anti-DNA antibody is Val-Ala-Tyr-lle-Ser-Arg-Gly-Gly-Val-Ser-Thr-Tyr- Tyr-Ser-Asp-Thr-Val-Lys-Gly-Arg-Phe-Thr-Arg-Gln-Lys-Tyr-Asn-Lys-Arg-Ala.
- peptides do not penetrate cells at 4°C and are likely taken up by endocytosis (Avrameas et al., 1998, Proc. Natl. Acad. Sci. USA 95:5601-5606; PCT Application No. WO99/07414).
- endocytosis endocytosis
- the peptides are translocated to the cytoplasm and nucleus. They can also convey proteins, enzymes and nucleic acids to the nucleus.
- a masking moiety can be any moiety that inhibits the biological activity of the intracellularly active entity by preventing the translocation of the transport peptide-intracellularly active entity construct across cell membranes, and that prevents the non-specific in vivo degradation of the optional linking moiety.
- the masking moiety prevents non-selective entry of the intracellularly active entity into the healthy cell. The toxicity of the prodrug is thereby reduced.
- the masking and/or the linking moiety is cleaved liberating the construct.
- the transport peptide portion of the construct carries the intracellularly active entity into the cell where the entity can exert its activity on the tumor or target cell.
- the construct can optionally comprise a cleavage site between the transport peptide and the intracellularly active entity.
- the cleavage site must be susceptible to cleavage within a cell and resistant to cleavage in the extracellular milieu or in the serum.
- the cleavage site can itself be resistant to extracellular cleavage, or the cleavage site can be resistant to extracellular cleavage when the construct is formulated as a prodrug.
- the cleavage site need not be selectively cleavable at or near target cells.
- the cleavage site can be optionally susceptible to selective cleavage within a target cell to impart even better activity and even greater target cell selectivity to the prodrugs of this embodiment.
- Suitable cleavage sites include peptide sequences that are stable in the extracellular environment and susceptible to protease cleavage within a cell.
- suitable protease-sensitive peptide sequences include but are not restricted to Arg-Xaa-(Lys/Arg)-Arg or other furin substrates (Nakayama, 1997, Biochem. J.
- a transport peptide is selectively masked with a masking moiety via a linking moiety.
- the masking moiety alone or together with the linking moiety, prevents intracellular transport of the transport peptide.
- the linking moiety is selectively cleaved, the active transport peptide is liberated.
- the transport peptide can then carry a biologically active entity with it into a cell and/or into the nucleus of the cell.
- the linking moiety can be any of the linking moieties discussed supra, and the masking moiety can be any of the masking moieties discussed supra.
- the linking moiety can be linked to any reactive group of the transport peptide that can tolerate leucyl derivatization without significant or complete loss of transport activity.
- Preferred masking moieties include succinylated PEG and preferred linking moieties include the tetrapeptide Ala-Leu-Ala-Leu.
- transport peptides have the unusual property of being transported intracellularly and into the nucleus. They are able to carry with them complexed or conjugated peptides, proteins, nucleic acids, and small molecules. However, the transport peptides are transported into a broad range of cell types, including most if not all normal cells. A transport peptide construct comprising a cytotoxic or cytostatic entities therefore suffers severe toxicity problems.
- the transport peptide construct is formulated as a prodrug according to the present invention.
- the transport activity of the peptide is reversibly blocked, for instance, by conjugation to a masking moiety via the linking tetrapeptide Ala- Leu-Ala-Leu. The activity is blocked due to conjugation on or close to specific, essential positively charged side chains of the transport peptides.
- the linking tetrapeptide is cleavable by peptidases released selectively in the extracellular environment of target cells. For example, modification of the transport peptide with PEG masks the transport activity of the peptide and also increases the solubility and half-life of the prodrug.
- An exemplary prodrug according to this embodiment of the present invention comprises doxorubicin linked to a derivatized transport peptide.
- the transport peptide can be derivatized with the masking moiety PEG via the linking tetrapeptide Ala-Leu-Ala- Leu at the appropriate reactive groups of the transport peptide determined as described above.
- a prodrug selectively transports an intracellularly active, pro-apoptotic protein into target cells in vivo.
- a pro-apoptotic protein is formulated in a prodrug as a construct comprising the pro-apoptotic protein and a transport peptide.
- the transport peptide facilitates entry of the pro-apoptotic protein into the cell.
- the transport peptide is chosen from those described above.
- the transport peptide can be linked to any reactive group of the pro-apoptotic protein, and preferred reactive groups include the free amino group at the amino terminus of the protein and free ⁇ amino groups of lysine side chains of the protein.
- a preferred apoptotic protein in this embodiment of the invention is Granzyme B.
- the masking moiety can be any masking moiety described above that, alone or together with the linking moiety, prevents the transport activity of the peptide and that prevents the non-specific cleavage of the linking moiety.
- the linking moiety can be any linking moiety described supra.
- Preferred masking moieties include PEG, preferred linking moieties include the tetrapeptide Ala-Leu-Ala-Leu.
- the transport peptide can be linked to the protein via an optional cleavage site susceptible to cleavage within the cell. If so, the cleavage site can be cleaved within the cell liberating the intact, active pro-apoptotic protein within the target cell.
- Granzyme B a single-chain serine protease of about 28.5 kDa, was first demonstrated to play a crucial role in the initiation of apoptosis induced by killer lymphocytes. This killing effect results from the synergistic effect of perforin, a membranolytic protein and the serine protease granzyme B (Blink et al., 1999, Immunol. Cell Biol. 77:206-215; Trapani et al., 1998, J. Biol. Chem. 273:27934-27938).
- Perforin allows granzyme B to reach the cytoplasm and the nucleus of cells by inducing the formation of transmembrane pores that constitute a passage for the enzyme.
- Granzyme B then induces apoptosis by starting pre-existing death pathways through the enzymatic cleavage and activation of pro-caspases, and also by directly cleaving nuclear substrates such as DNA-PK and poly-ADP ribose polymerase (Frcelich et al., 1996, Biochem. Biophys. Res. Commun. 227:658-665; Yang et al., 1998, J. Biol. Chem. 273:34278- 34283).
- the transport peptide potentially plays the role of perforin by allowing granzyme B to enter the cell and to induce apoptosis.
- Preferred prodrugs of this embodiment of the present invention comprise granzyme B linked to the PEG-Ala-Leu-Ala-Leu derivative of the transport peptide, described above, via an amide bond from the carboxy terminus of granzyme B to the amino terminus of the derivatized transport peptide.
- the granzyme B prodrug can be administered alone or in combination with doxorubicin or any doxorubicin prodrug described above.
- the prodrug compounds are dual prodrugs.
- a dual prodrug compound can deliver two or more entities to target cells.
- the biologically active entity is a cytostatic or cytotoxic entity as described in detail above.
- the masking moiety of the dual prodrug also has biological activity.
- the masking moiety can be biologically active intracellularly or extracellularly so long as the masking moiety, alone or together with the linking moiety, prevents the activity of the biologically active entity, is inactive prior to its release from the prodrug, and prevents the in vivo degradation of the prodrug.
- Suitable masking moieties can be selected from the extracellular and intracellular biologically active entities discussed in detail herein. Suitable masking moieties also include small molecule therapeutic entities.
- suitable masking moieties can be selected from anthracyclines, doxorubicin, daunorubicin, folic acid derivatives, vinca alkaloids, calicheamycin, mitoxantrone, cytosine arabinoside, adenosine arabinoside, fludarabine phosphate, melphalan, bleomycin, mitomycin, L-canavanine, taxoids, camptothecin, proteasome inhibitor, farnesyl transferase inhibitor, epothilones, maytansinoids, discodermolide, platinum derivatives, duocarmycins, combrestastatin and epipodophyllotoxins.
- Dual prodrugs of the present invention include any pair of entities that have a biological activity and a therapeutic effect on a tumor or target cell.
- a dual prodrug can comprise two biologically active polypeptides, two biologically active small molecules, two extracellularly active biologically active entities, a biologically active polypeptide and a biologically active small molecule, and other pairs of biologically active entities apparent to one of skill in the art.
- Particularly useful prodrugs of the present invention are those that comprise a pair of entities that act in concert at a target cell.
- one of the entities can be a ligand for a cell surface receptor that facilitates transport of the other entity when bound to the receptor.
- one entity can alter the permeability of the cell membrane to facilitate transport of the other entity.
- a small molecule and a polypeptide can have synergistic effects on the same target cell.
- the masking moiety and biologically active entities may be linked to the linking moiety as previously described (see, e.g., FIG. 3B, FIG. 3C, and FIG. 3D). If neither the biologically active entity nor the masking moiety retains sufficient activity following cleavage when linked to the amino terminus of the linking moiety, they must both be linked to the linking moiety via carboxyl groups. This can be conveniently achieved using a "dual polarity" linking moiety as illustrated in FIG. 3E.
- Dual polarity linking moiety 58 is linked to two biologically active entities 38 to yield dual prodrug 52.
- Dual polarity linking moiety 58 comprises three segments: a first segment 53, a second segment 55 and a third segment 57.
- Segments 53 and 57 are each linking moieties as described herein, and may be the same or different.
- Linking moiety segments 53 and 57 are linked together via second segment 55 at their amino termini.
- second segment 53 is typically a spacer or an adaptor moiety having two reactive groups capable of forming a covalent linkage with an amino group, such as a dicarboxylic acid (e.g., citraconyl, dimethylmaleyl, glutaryl, succinyl and diglycolyl).
- a dicarboxylic acid e.g., citraconyl, dimethylmaleyl, glutaryl, succinyl and diglycolyl.
- dual prodrug 52 When placed in the vicinity of a target cell, dual prodrug 52 is cleaved to release 2 moles of released biologically active entity 39 for every mole of dual prodrug 52.
- dual prodrug 52 may optionally include spacing moieties intervening one or both biologically active moieties, as previously described.
- linking segments 53 and 55 are identical, as are biologically active entities 38. However, those of skill in the art will recognize that they need not be. Linking segments 53 and 55 and biologically active entities 38 may each be, independently of one another, the same or different.
- one of the biologically active entities is the small molecule active entity doxorubicin. Doxorubicin can be linked to any of the biologically active agents discussed supra. For instance, in one embodiment a dual prodrug delivers the two antineoplastic entities, TNF ⁇ and doxorubicin.
- doxorubicin can be linked to the IGF-1 antagonist described supra or to the Iytic peptide LK15 described supra.
- One doxorubicin molecule can even be linked to another doxorubicin molecule via one of the linking moieties of the present invention to form a selective prodrug.
- Dual prodrugs comprising TNF ⁇ Preferred dual prodrugs comprise pairs of biologically active agents that act in concert with each other. For instance, the cytotoxic effect of TNF ⁇ on many tumor cell lines is enhanced by other cytokines and antitumor drugs. For instance, IFN- ⁇ , IFN- ⁇ and IL-1 have been shown to enhance the cytotoxic effects of TNF ⁇ or to abrogate the cellular resistance to TNF ⁇ . There is convincing evidence that there is a synergy between TNF ⁇ and topoisomerase-targeted drugs such as doxorubicin, VM-26, etoposide, teniposide and daunorubicin.
- topoisomerase-targeted drugs such as doxorubicin, VM-26, etoposide, teniposide and daunorubicin.
- Doxorubicin can also suppress the resistance of tumor cells to TNF ⁇ , due to endogenous TNF ⁇ , provided it is administered before or during the treatment with TNF ⁇ (Borsellino et al., 1995, Anticancer
- TNF ⁇ has been shown to act synergistically with classical anticancer entities, and particularly anthracyclines, a dual prodrug comprising TNF ⁇ and doxorubicin is prepared.
- Doxorubicin can be linked to the carboxy terminal end of a peptide linking moiety, and TNF ⁇ can be linked to the amino terminal end of the linking moiety via a dicarboxylic acid spacer. Activation of the prodrug in the vicinity of a target cell liberates leucyl-doxorubicin and TNF ⁇ modified with a portion of the linking moiety.
- the biologically active entity doxorubicin is linked to the tetrapeptide linking moiety Ala-Leu-Ala-Leu as described (U.S. Patent No. 5,962,216) to yield Ala-Leu-Ala-Leu-Dox.
- a TNF ⁇ dual prodrug is prepared by linking Ala-
- doxorubicin can be linked to the thrombospondin-1 -derived peptides, discussed supra, to generate potent dual prodrugs.
- dual prodrugs are prepared by linking Ala- Leu-Ala-Leu-Dox to the carboxy terminus or to amino acid side chains of peptide derivatives of TSP-1 .
- the biologically active entities of this embodiment of the present invention comprise peptides derived from consensus sequences from the primary structure of TSP-1 .
- dual prodrugs can be prepared by linking doxorubicin to a substance P antagonist.
- Trp-Phe-D-Trp-Leu-Leu-NH 2 (“SPD").
- Ala-Leu-Ala-Leu-Dox can be linked to the amino terminus of SPD via a dicarboxylic methylmaleyl moiety.
- prodrug compounds can be prepared according to standard synthetic or recombinant techniques known to those of skill in the art.
- peptide linking moieties can be synthesized by conventional solid phase or solution phase peptide chemistry.
- Biologically active entities and masking moieties can be obtained from commercial sources or from other well-known methods such as purification from natural sources, recombinant expression and other techniques.
- Dual polarity linkers and spacer moieties can be synthesized or obtained from commercial sources or from other well- known methods.
- the prodrugs are prepared synthetically by condensing the masking moiety and biologically active entity with the linking moiety.
- Well known protecting groups can be used advantageously in the preparation of prodrug compounds.
- a prodrug compound of the present invention can be prepared according to the scheme presented in FIG. 4A.
- the free amino group of linking moiety 30 is first protected with a standard protecting group such as Fmoc to yield Fmoc-protected compound 70.
- a covalent bond is then formed by condensing a reactive group of Fmoc-protected 70 with a complementary reactive group of biologically active entity 38 to form the Fmoc-protected complex 72. Deprotection of the complex 72 yields compound 74.
- the masking moiety can be linked to the linking moiety prior to reaction with the biologically active agent.
- a plurality of Fmoc-protected complexes 72 may be condensed with a single biologically active entity
- an exemplary prodrug composition of the invention 40 is constructed by coupling an activated form of masking moiety 34 including a reactive carboxy group to the amino terminus of linking moiety 30 to yield compound 36.
- Compound 36 is linked to a biologically active entity 38 which includes a reactive amine group to yield prodrug 40.
- FIG. 4C illustrates the preparation of a prodrug of the invention which comprises a spacing moiety.
- Compound 36 which comprises masking moiety 34 linked to linking moiety 30, is coupled with spacing moiety 42 to yield compound 44.
- Compound 44 is then coupled with biologically active entity 38 to yield a prodrug compound wherein the biologically active entity 38 is separated from linking moiety 30 by spacing moiety 42.
- Activation of the prodrug in the vicinity of a target cell liberates compound 48 comprising biologically active entity 38, spacing moiety 42 and a leucine residue.
- the synthesis may be controlled by employing a protection scheme analogous to that illustrated in FIG. 4A.
- Compound 58 comprises two linking moieties 53 and 57 linked in reverse polarity by dual polarity linking moiety 55.
- compound 58 has two free carboxyl groups for linking to the other moieties of the prodrug.
- Two molecules of biologically active entity 38 are coupled to the free carboxyl groups of compound 58 to yield dual prodrug 52.
- Cleavage of dual prodrug 52 in the vicinity of target cells liberates two molecules of released biologically active entity 39.
- Both molecules of released biological entity 39 comprise biologically active agent 38 derivatized with a leucine residue.
- linking moiety is a peptide and the biologically active entity is a polypeptide and a terminus of the linking moiety is linked to a complementary terminus of the biologically active entity via an amide bond
- the prodrug, or a portion thereof can conveniently be prepared by recombinant synthesis.
- a nucleic acid coding for the amino acid sequence of the linking moiety and the biologically active agent can be prepared and used to express the covalent linking moiety - biologically active agent complex by standard techniques (see, e.g., Ausubel et al., 1987, Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York).
- the masking moiety can then be linked, for instance, to the amino terminus of the linking moiety by standard solution phase peptide chemistry. If the masking moiety is also a peptide or polypeptide and a terminus of the masking moiety is also linked to a complementary terminus of the linking moiety via an amide bond, the entire prodrug can conveniently be prepared by recombinant synthetic techniques.
- the nucleic acid expressing the prodrug should encode the amino acid sequences of the masking moiety, the linking moiety and the biologically active entity in tandem.
- Prodrugs produced by recombinant synthesis can be expressed in any eukaryotic or prokaryotic system in which the linking moiety is not cleaved by proteases, peptidases or other factors.
- the prodrugs of the invention can be used in a wide variety of applications to inhibit or prevent the growth of a tumor or target cell.
- the prodrugs can be used to treat or prevent diseases related to tumor cell growth in humans and animals.
- the prodrugs of the invention can be administered or applied singly, as mixtures of prodrugs, in combination with other antineoplastic entities or in combination with other pharmaceutically active entities.
- a prodrug can be administered as the prodrug per se ot may be in admixture with a variety of carriers, diluents or excipients as are well known in the art.
- compositions comprising the prodrugs of the invention may be manufactured by means of conventional mixing, dissolving, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
- Pharmaceutical compositions may be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries which facilitate processing of the active peptides into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
- Systemic formulations include those designed for administration by injection, e.g. subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection.
- the prodrugs of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer.
- the solution may contain formulatory entities such as suspending, stabilizing and/or dispersing entities.
- the prodrug may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
- the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
- the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- Liposomes and emulsions are well known examples of delivery vehicles that may be used to deliver peptides of the invention.
- Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity.
- the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid polymers containing the therapeutic entity.
- sustained-release materials have been established and are well known by those skilled in the art.
- Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.
- the prodrugs of the invention may contain charged side chains, they may be included in any of the above-described formulations as the free bases or as pharmaceutically acceptable salts.
- Pharmaceutically acceptable salts are those salts which substantially retain the activity of the free bases and which are prepared by reaction with inorganic acids. Pharmaceutical salts tend to be more soluble in aqueous and other protic solvents than are the corresponding free base forms. 5.9.2 Effective Dosages
- the prodrugs of the invention, or compositions thereof will generally be used in an amount effective to achieve the intended purpose.
- amount used will depend on the particular application.
- an therapeutically effective amount of a prodrug, or composition thereof is applied or administered to an animal or human in need thereof.
- therapeutically effective amount is meant an amount of peptide or composition that inhibits the growth of, or is lethal to, a target cell.
- the actual therapeutically effective amount will depend on a particular application. An ordinarily skilled artisan will be able to determine therapeutically effective amounts of particular prodrugs for particular applications without undue experimentation using, for example, the in vitro assays provided in the examples.
- the prodrugs of the invention, or compositions thereof are administered or applied in a therapeutically effective amount.
- therapeutically effective amount is meant an amount effective to ameliorate the symptoms of, or ameliorate, treat or prevent tumor or target cell growth or diseases related thereto. Determination of a therapeutically effective amount is well within the capabilities of those skilled in the art, especially in light of the detailed disclosure provided herein.
- a therapeutically effective dose can be estimated initially from in vitro assays.
- a dose can be formulated in animal models to achieve a circulating prodrug concentration range that includes the l 50 as determined in cell culture (i.e., the concentration of test compound that is lethal to 50% of a cell culture), the MIC, as determined in cell culture (i.e., the minimal inhibitory concentration for growth) or the l 100 as determined in cell culture (i.e., the concentration of peptide that is lethal to
- Initial dosages can also be estimated from in vivo data, e.g., animal models, using techniques that are well known in the art. One having ordinary skill in the art could readily optimize administration to humans based on animal data.
- the amount of prodrug administered will, of course, be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.
- the antitumoral therapy may be repeated intermittently.
- the therapy may be provided alone or in combination with other drugs, such as for example other antineoplastic entities or other pharmaceutically effective entities.
- a therapeutically effective dose of the prodrugs described herein will provide therapeutic benefit without causing substantial toxicity.
- Toxicity of the prodrugs described herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., by determining the LD 50 (the dose lethal to 50% of the population) or the LD 100 (the dose lethal to 100% of the population).
- the dose ratio between toxic and therapeutic effect is the therapeutic index. Compounds which exhibit high therapeutic indices are preferred.
- the data obtained from these cell culture assays and animal studies can be used in formulating a dosage range that is not toxic for use in human.
- the dosage of the prodrugs described herein lies preferably within a range of circulating concentrations that include the effective dose with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
- TNF ⁇ biologically active entity
- TNF ⁇ is linked to a plurality of polyethylene glycol masking moieties via tetrapeptide linking moieties.
- the PEG moieties are linked to TNF ⁇ via the tetrapeptide linking moiety Ala-Leu- Ala-Leu.
- the tetrapeptide linker Ala-Leu-Ala-Leu is selected because it is known to allow the generation of protein-drug conjugates that are resistant to blood peptidases (Trouet et al., 1982, Proc. Natl. Acad. Sci. USA 79:626-629).
- leucyl- derivatives are first prepared. Leucine residues are linked covalently through peptide bonds between their carboxyl group and a terminal amino group or side chain amino group (e.g. lysine ⁇ -amine) of TNF ⁇ . The extent of modification is controlled by varying the ratio of reactive leucine molecules to TNF ⁇ .
- the leucyl-derivatives of TNF ⁇ are prepared by acylation of free amino groups using the ⁇ /-hydroxysuccinimide ester of acetol-leucine in an organic-aqueous medium.
- Hydroxyalkylated-amino acid-activated esters have excellent reactivity and are particularly well adapted to the acylation of proteins (Hermanson, 1996, Bioconjugate Techniques. Academic Press, San Diego, New York; Geoghegan et al., 1979, Biochemistry 18:5392- 5399). After deprotection of acetol-leucyl residues in mild conditions with NalO 4 , derivatives of TNF ⁇ are purified by size exclusion chromatography. Their purity is assessed by gel electrophoresis.
- TNF ⁇ and of the leucyl-derivatives of TNF ⁇ are compared in order to select the extent of modification that is used for the preparation of prodrugs.
- a ratio leucine to PEG that preserves a significant amount of TNF ⁇ activity is selected as a basis for the TNF ⁇ prodrugs discussed below.
- TNF ⁇ and its derivatives The activity of TNF ⁇ and its derivatives is determined using the classical assay as described (Creasey et al., 1987, Cancer Res. 47:145-149).
- L929 murine fibroblasts are seeded and grown in 96-well microtiter plates. They are then exposed to actinomycin D (1 ⁇ g/ml) in the presence of increasing concentrations of TNF ⁇ or Leu x -TNF ⁇ . After 24 hours of incubation at 37°C, cell lysis (lactate dehydrogenase [LDH] release assay) and viability (transformation of WST-1 by viable cells in a soluble formazan salt) are determined.
- LDH lactate dehydrogenase
- Receptor binding assays are also performed using HEp-2 cells (human epidermoid carcinoma cell line expressing mainly the 55 kDa TNF ⁇ receptor) to determine how the modifications influence receptor binding.
- Cells are exposed to [ 125 I]-TNF ⁇ and increasing concentrations of TNF ⁇ or Leu x -TNF ⁇ at 4°C. After several washes cell- associated radioactivity is quantified.
- HL60 cells human promyelocytic leukemia cell line expressing mainly the 75 kDa receptor
- TNF ⁇ is conjugated to one or more PEG molecules via the selected linker tetrapeptide attached through the C-terminal leucine of the tetrapeptide to primary amino groups of TNF ⁇ .
- the PEG-linker moieties are conjugated to a TNF ⁇ at an appropriate ratio as determined by the activity assays of the leucyl derivatives of TNF ⁇ discussed above. For instance, if leucyl-TNF ⁇ conjugates can tolerate modification of up to 56% of its amino groups while retaining significant activity, then the PEG-linker moieties are linked to TNF ⁇ at a molar ratio sufficient to modify 56% of the amino groups of TNF ⁇ .
- the optimum molecular weight of the PEG [H(OCH 2 -CH 2 ) n OH] molecule is the lowest molecular weight that results in inactivation of the drugs with the conjugation level previously determined.
- PEG of molecular weight 1000, 4000, 8000, 10000 is available under its dialcohol form, while an ether form [H(OCH 2 -CH 2 ) n OMe] with a molecular weight of 5000 can also be found.
- PEG can easily be coupled to a primary amine through a spacer or adaptor such as a succinate moiety.
- Succinylated PEG can be obtained commercially. Alternatively, well described and documented synthesis procedures are available from the , literature
- the PEGylated compounds can be purified by size exclusion chromatography.
- Stability in blood and reactivation by tumor-secreted peptidases can be rapidly assessed in vitro.
- receptor-binding assays are carried out with the conjugates of TNF ⁇ to check inactivation as described, supra.
- culture media conditioned by MCF-7/6 (breast carcinoma), LS-174-T (colon carcinoma), LNCaP (prostate carcinoma) and NCI-H209 (small-cell lung carcinoma), or other cell lines are used to check the reactivation of the conjugates by tumor-released peptidases.
- the conjugates are analyzed by western immunoblotting or by an activity assay.
- the prodrugs are then tested in vivo (acute toxicity/lethality studies and chemotherapeutic activity), both as single entities and in combination with other cytotoxic and/or cytostatic anticancer entities such as doxorubicin.
- OF-1 mice are used for lethality studies with the conjugates. Increasing doses of the conjugates or of the parent compound are administered by the i.v. route, and the LD 5Q values are determined after 28 days. Single as well as multiple injection protocols are considered.
- Balb/c nu-nu mice are implanted subcutaneously in both flanks with fragments of human tumors grown from the cell lines previously mentioned. Tumors are allowed to grow until they reach a mean diameter of at least 6 mm.
- treatments consisting of saline, doxorubicin, the prodrug alone or the prodrug in combination with doxorubicin, are administered as i.v. bolus injections.
- the animals are treated once a week for five consecutive weeks.
- Clinical signs, body weight and tumor growth are monitored for at least 60 days.
- Treatment efficacy is assessed based on tumor growth delays and on the ratio of tumor volumes in treated groups versus control animals.
- -Mal-Leu-OH derivatives of TNF ⁇ are prepared.
- the amino terminus of leucine methyl ester (Leu-OMe) is modified with dimethylmaleic anhydride to yield dimethylmaleyl leucine (Mal-Leu-OMe).
- Free amino moieties of TNF ⁇ are then modified by forming amide bonds between free amino groups of TNF ⁇ and free carboxyl groups of -Mal-Leu-OMe.
- enzymatic ester hydrolysis Shin C. G., 1997, Bull. Chem. Soc. Jpn. 70, 1427-1434
- the resulting -Mal-LeuOH TNF ⁇ derivatives are compared to native TNF ⁇ in terms of activity.
- the maximum number of free amino moieties of TNF ⁇ that can be modified with -Mal-LeuOH without significantly altering the activity is determined as discussed in Example 1 , supra.
- TNF ⁇ is similarly modified with Mal-Leu-Ala- Leu-Ala-Leu-Dox in order to obtain the dual prodrug.
- the peptide-Dox conjugate is prepared according to U.S. Patent No. 5,962,216.
- Alternative dual prodrugs are also prepared by coupling leucine directly to the free carboxyl groups available in TNF ⁇ .
- TNF ⁇ has 5 aspartic acid and 9 glutamic acid residues.
- TNF ⁇ derivatives are purified by size-exclusion chromatography, and the purity is determined by electrophoretic techniques.
- the activity and/or inactivity, stability and reactivation of the dual prodrugs is assayed as described in Example 1 , supra. In vivo toxicity and activity of the dual prodrugs is also evaluated as described in Example 1 , supra.
- prodrug comprising an oligopeptide antagonist of insulin-like growth factor-1 (IGF-1 ) linked to PEG via a tetrapeptide linking moiety.
- IGF-1 insulin-like growth factor-1
- the selected IGF-1 antagonist is a cyclic dodecapeptide made of D-amino acids.
- the peptide has the formula cyclo[H-D-Cys-D-Ser-D-Lys-D-Ala-D-Pro-D-Lys-D-Leu-D-Pro-D-Ala-D- Ala-D-Tyr-D-Cys-OH].
- the peptide is cyclized via a disulfide bridge between the side chains of the two cysteine residues. It is synthesized by standard solid phase peptide synthesis techniques.
- Leucyl conjugates of the IGF-1 antagonist Free amino groups of the IGF-1 antagonist are modified with leucine residues as described in Example 1 , supra. Initially, only the terminal amino group of the IGF-1 antagonist is modified. If modification of the terminal amino group results in a significant loss of activity, then other reactive groups of IGF-1 are modified and assayed for retention of functional activity.
- the conjugates are purified by semi-preparative reverse phase HPLC. The purity of the conjugates is determined by reverse phase HPLC-MS. The structural quality of the conjugates is verified by NMR and mass spectrometry.
- MCF-7/6 human breast cancer cells are seeded and grown in serum-free medium. They are then incubated at 4°C with [ 125 I]-IGF-1 in the presence of increasing concentrations of IGF-1 , the IGF-1 antagonist or its leucyl- derivative. After washes, cell-associated radioactivity is quantified.
- MCF-7/6 cells are also used to compare the inhibitory effects of the IGF-1 antagonist and of its leucyl-derivative on IGF-1 -induced proliferation.
- Cells are seeded in serum-free medium in the presence of 10 ng/ml IGF-1 and increasing concentrations of the IGF-1 antagonist or its leucyl-derivative. Cell proliferation is then estimated by the incorporation of [ 3 H]-thymidine into DNA.
- the IGF-1 antagonist is conjugated to one or more PEG molecules via the selected linker tetrapeptide attached through the C-terminal leucine of the tetrapeptide to primary amino groups the antagonist as described in Example 1.
- Radiolabeled ( 14 C or 3 H) amino acids are incorporated in a fraction of the prodrugs.
- the resulting radioactive conjugates are then used as tracers to allow sensitive detection of metabolites in the in vitro studies. All PEGylated compounds are purified by size exclusion chromatography.
- IGF-1 prodrug The inactivation of the IGF-1 prodrug is tested using the activity assays described above for the leucyl derivatives of IGF-1. Blood stability and reactivation in tumor cells conditioned media is tested as described in Example 1 and additionally by HPLC analysis. Toxicity and chemotherapeutic activity studies are then performed with the prodrug and with the prodrug in combination with doxorubicin. These studies are once again performed as described in Example 1 and additionally by HPLC.
- prodrug comprising a Iytic peptide linked to a PEG masking moiety via a tetrapeptide linking moiety.
- the Iytic peptide is composed exclusively of leucine and lysine residues, like those described as cytolytic in the literature (Castano et al., 1999, supra). However, only D- amino acids are used to yield a relatively low sensitivity to proteolysis in vivo.
- OH is prepared according to standard solid phase peptide synthesis techniques using orthogonal protecting groups on the ⁇ -amino groups of lysine side chains as necessary.
- Leucyl conjugates of the Iytic peptide Free amino groups of the Iytic peptide are modified with leucine residues as described in Example 1 , supra. Initially, the ⁇ -amino group of each lysine side chain of the Iytic peptide is modified. If necessary, the terminal amino group is also modified with leucine. The orthogonal protecting groups of the synthesis step are exploited to selectively modify specific amino groups.
- the conjugates are purified by semi-preparative reverse phase HPLC. The purity of the conjugates is determined by reverse phase HPLC-MS. The structural quality of the conjugates is verified by NMR and mass spectrometry.
- the activity of the Iytic peptide and its derivatives are assessed in hemolytic assays as well as by quantifying LDH release from tumor cells.
- Erythrocytes are isolated from fresh human blood collected on citrate from healthy donors. Peptide dilutions are dispensed in 96-well plates before the addition of an erythrocyte suspension to each well. After a 30-minute incubation at 37°C and a centrifugation, the supernatants are transferred to new plates for A» determination. Blank (no hemolysis) values are obtained from unexposed cells and 100% hemolysis is determined from cells suspended in distilled water. To check if serum alters the Iytic activity of the peptide by potential alterations of the monomer-polymer equilibrium, the assay is also performed with various concentrations of human serum (10 to 100%).
- the Iytic activity is also determined on nucleated cancer cells. We assess lysis based on the extent of LDH release from cells exposed to increasing concentrations of
- MCF-7/6 cells are grown in 96-well plates and then exposed to increasing concentrations of the compounds to be tested for 1 hour at 37°C. Supernatants and the cell monolayers are separated and used for the determination of LDH activity. The percentage of total activity released in the culture medium is considered.
- the lytic peptide is conjugated to one or more PEG molecules via the selected linker tetrapeptide attached through the C-terminal leucine of the tetrapeptide to primary amino groups of the lytic peptide as described in Example 1.
- the choice of primary amino groups and stoichiometry is determined by the activity results from the leucyl derivatives of the lytic peptide as discussed for TNF ⁇ in Example 1.
- Reverse sequences made of D-amino acids have been developed, derived from the second type-1 repeat of thrombospondin-1 (TSP-1 ). These peptides have antiproliferative and antiangiogenic properties (Dawson et al., 1999, supra). Mal II, a 19- residue peptide is derived from the properdin-like repeat of TSP-1 and shown to possess potent antiangiogenic properties when any one of three L-amino acids are substituted by their D-enantiomers. In vitro and in vivo anti-angiogenic activities are achieved by low concentrations. The most interesting such peptide is D-lle 15 -Mal II (Dawson et al., 1999, supra). It is quite amenable to alterations since it can be shortened to as little as seven amino acids with no loss of activity, and the addition of an ethylamide end group to the 7- mer further increases its potency.
- a heptapeptide derivative of D-lle 15 -Mal II with the structure Acetyl-Gly-Val-D-lle- Thr-Arg-lle-Arg is synthesized by standard solid phase peptide synthesis techniques. Also synthesized via standard techniques are an ethylamide-capped derivative of the heptaptide with the structure Acetyl-Gly-Val-D-lle-Thr-Arg le-Arg-NHEt and the D- heptapeptide D-Arg-D-lle-D-Arg-D-Thr-D-lle-D-Val-Gly derived from the heptapeptide.
- the heptapeptide and the two derivatives are each first coupled to a leucine residue.
- the leucine residue is coupled to the side chain of an Arg residue via a dimethylmaleyl dicarboxylic adaptor according to standard techniques.
- the leucine residue is linked through its amino group to the carboxy terminus.
- the activity of the resulting peptides are compared to the activities of the corresponding native peptides.
- the activities of the compounds are assessed on endothelial cells such as the EAhy926 cell line (Edgell et al., 1983, Proc. Natl. Acad. Sci. USA 80:3734-3737). After incubation with various concentrations of the compounds in the presence of vascular endothelium growth factor (VEGF), cell viability (WST-1 reagent) is determined as well as the effect on [ 3 H]-thymidine incorporation into VEGF.
- VEGF vascular endothelium growth factor
- the three native heptapeptides are then each conjugated via standard synthetic techniques to Leu-Ala-Leu-Ala-Leu-Dox to produce the dual prodrugs.
- the Leu-Ala-Leu-Ala-Leu-Dox construct is coupled to the side chain of an Arg residue via a dimethylmaleyl dicarboxylic spacer according to standard techniques.
- the quality of all compounds are determined by reverse phase HPLC(-MS). When necessary, semi-preparative HPLC is used for purification.
- the structures are confirmed by amino acid, NMR and MS analyses.
- Example 1 Its chemotherapeutic activity is then compared to that of Dox and of the corresponding native antiangiogenic peptide, alone or in combination.
- the IGF-1 antagonist described in Example 3, supra, is used to prepare a dual prodrug.
- conjugation takes place at the carboxy-terminus of the antagonist rather than on its free N-terminal amino group.
- adding a tumor peptidase-sensitive peptide derivative of Dox to the carboxyl group of the relatively small antagonist prevents it from binding the IGF-1 receptor (through a steric hindrance phenomenon). If so, the dual conjugate is inactive, with no requirement for a further masking of the extracellularly-acting antagonist. If masking is required, the two lysine residues of the antagonist are modified with pH- sensitive, e.g. dimethylmaleyl, groups that are removed in the tumor environment.
- a leucyl derivative of the IGF-1 antagonist is prepared by standard coupling at the C-terminus of the peptide utilizing suitable orthogonal protecting groups. If necessary, the disulfide bridge is recylized by standard techniques. The resulting C-terminal leucyl derivative of the IGF-1 antagonist is then coupled at its C-terminus with the N-terminus of Ala-Leu-Ala-Leu-Dox by standard techniques. It is believed that the resulting dual prodrug, when in the tumor microenvironment, yields the leucyl-derivatives of both Dox and the IGF-1 antagonist.
- the leucyl-derivative and the prodrug are purified by semi-preparative reverse phase HPLC.
- the purity of the conjugates is determined by reverse phase HPLC-MS.
- the structural quality of the conjugates is verified by NMR and mass spectrometry.
- First, the activity of the leucyl-derivative is assayed as described in Example 3.
- Second, the inability of the full prodrug to bind IGF-1 receptors is assayed. Its blood stability and reactivation by tumor cells conditioned media are then assayed. Fluorescence detection is used to detect the anthracycline and its derivatives. If the activity of the IGF-1 antagonist is not inhibited in the dual prodrug, the ⁇ -amino groups of the 2 lysine residues are masked, for example with pH sensitive moieties such as dimethylmaleyl groups.
- the in vivo toxicity of the dual prodrug is evaluated, and its chemotherapeutic activity is compared to that of Dox and of the IGF-1 antagonist, alone or in combination.
- Nude mice bearing MCF-7/6 human breast tumors are used for the activity assays.
- a dual prodrug is also prepared with the lytic peptide described in Example 4, supra.
- the optimal site of conjugation is as determined in Example 4. For instance, the free carboxy terminus is a likely effective site of conjugation.
- the lytic activity of the lytic peptide is reversibly masked as described in Example 4.
- the LK15 peptide is be conjugated to Leu-Ala-Leu-Ala-Leu-Dox by standard synthetic techniques via a dimethylmaleyl dicarboxylic adaptor.
- the results are compared to the naked lytic peptide, to doxorubicin and to the combination of the two entities.
- SPD 1 1 -residue amidated peptide D-Arg-Pro-Lys-Pro-D-Trp-Gln-D-Trp-Phe- D-Trp-Leu-Leu-NH 2
- SPD 1 1 -residue amidated peptide D-Arg-Pro-Lys-Pro-D-Trp-Gln-D-Trp-Phe- D-Trp-Leu-Leu-NH 2
- SPD has no free carboxyl group to use to couple the linker peptide-Dox conjugate, and the amidated carboxy terminal Leu is very likely important for activity. Therefore, the ⁇ /-terminus of SPD (D-Arg) is modified with a dicarboxylic methylmaleyl moiety according to a previously described synthesis procedure using classical solution peptide chemistry with standard orthogonal side chain protecting groups (Nyeki, 1998, J. Peptide Sc. 4:486- 495).
- the amino terminus of a leucine residue is then coupled to the free carboxyl group introduced on the amino-terminal D-arginine.
- the leucine derivative is then coupled to the free terminal amino-group of Ala-Leu-Ala-Leu-Dox.
- Leucyl-Dox and leucyl-dimethylmaleyl-SPD or SPD.
- Leucyl-dimethylmaleyl-SPD is therefore also synthesized and tested for its activity or further activation.
- the purity of the dual prodrug and its derivatives is determined by HPLC analysis.
- the dual prodrug is unexpectedly active as an inhibitor, its activity is masked, for example by reversibly modifying the side chain amino groups as described in Example 3.
- Fluorescence and UV detection allow detection of doxorubicin and the substance P antagonist.
- the activity of the metabolites generated in conditioned media is assayed on human lung cell lines (COR-L23 or NCI-H69 for example). Cytotoxicity and proliferation assays are performed as described in Example 1 and in Example 3.
- Example 9 Tumor-selective transport peptide (e.g. Tat) for intracellular delivery of doxorubicin
- an HIV Tat-derived transport peptide (Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Pro-Pro-Gln-Cys) prodrug for carrying doxorubicin directly to the nucleus of a target cell.
- Formulation of the construct as a prodrug according to the present invention by coupling with PEG-Ala-Leu- Ala-Leu provides selectivity for target cells to the construct and increases its stability.
- the HIV- Tat-derived transport peptide of the construct carries doxorubicin to the nucleus of the cell, doxorubicin's site of action.
- leucyl derivatives of the HIV- Tat-derived transport peptide are first synthesized to identify those leucyl derivatives that retain their ability to enter cells.
- Leucine residues are linked covalently through peptide bonds between their carboxyl group and a side chain amino (e.g. lysine residues) or guanidino (e.g. arginine residues) group present or added to the HIV- Tat-derived transport peptide.
- Derivatives are then compared with regard to their capacity to be internalized.
- transport activity can be reversibly blocked by capping the side- chains of lysine or arginine residues with acid-labile moieties such as dimethylmaleyl or citraconyl groups. These groups are introduced from the corresponding anhydrides and are unstable when the pH falls below 6.5, values often encountered in the vicinity of tumor cells (Lavie et al., 1991 , supra).
- the uptake of the biotinylated peptide and its leucyl-derivatives in MCF-7/6 human breast cancer cells is determined after reaction with streptavidin-conjugated horse radish peroxidase.
- Cells are incubated for 1 to 18 hours with biotinylated peptides at 0.1 to 20 ⁇ g/ml, washed, fixed with ethanol, permeabilized with Triton X-100 and incubated with a streptavidin-peroxidase conjugate (5 ⁇ g/ml) for 1 hour. After more washes, the peroxidase activity is quantified using o-phenylenediamine and H 2 O 2 as the substrates.
- PEG-Ala-Leu-Ala-Leu is introduced at that position as described in Example 1 , supra. If several leucyl-derivatives display adequate transport activity, then several PEG-Ala-Leu-Ala-Leu conjugates are prepared.
- the ideal PEG molecular weight to prevent cell penetration is determined by the cellular uptake assays described above.
- PEG-linker tetrapeptide conjugates of the HIV- Tat-derived transport peptide are tested similarly for cell uptake. In addition, their blood stability and reactivation by cancer cells conditioned media is also be assessed. Conjugates incorporating radiolabeled residues are used as tracers in these studies to allow sensitive detection of the conjugates and of potential metabolites.
- the peptide conjugates are incubated at 37°C in whole blood from healthy donors collected in citrated tubes. At selected time points, samples are centrifuged to eliminate cells and analyzed by HPLC. The disappearance of the conjugates over time is quantified. Media conditioned by MCF-7/6 (breast carcinoma) and LS-174-T (colon carcinoma) cell lines are used to check tumor peptidase reactivation of the conjugates. After incubation at 37°C for increasing time lags, the conjugates and their metabolites are analyzed by HPLC.
- mice are implanted subcutaneously in both flanks with fragments of human tumors that will be allowed to grow until they reach a mean diameter of at least 6 mm.
- Treatments consisting of a biotinylated and/or radiolabeled peptide conjugate are administered as i.v. bolus injections.
- tumors, heart, liver, kidneys, spleen, brain, lungs, and plasma are collected.
- the biotinylated and/or radiolabeled peptide is isolated on steptavidin- coated multiwell plates and quantified.
- Doxorubicin conjugates of the tumor-selective vector peptide are then prepared by coupling to the appropriate PEG-Ala-Leu-Ala-Leu derivatives of the HIV- Tat-derived transport peptide.
- the carboxy terminus of the transport peptide is coupled to the free hydroxyl group of doxorubicin via standard synthesis techniques.
- a glutaric anhydride spacer is linked to the free hydroxyl moiety of doxorubicin via an ester linkage and to the amino terminus of the transport peptide.
- a third construct is prepared by coupling doxorubicin to the transport peptide via the daunosamine moiety of doxorubicin through an amide linkage.
- a peptide spacer that is cleaved intracellularly (in the Golgi apparatus or in the nucleus) to liberate free doxorubicin is used between the drug and the carrier peptide.
- a suitable spacer is identified be screening peptide spacers in the presence of tumor cell conditioned media on one hand or in the presence of tumor cell homogenates (or subcellular fractions). The peptidic spacer is selected on the basis of its resistance to the conditioned media and its sensitivity to the cell homogenates at neutral pH.
- the stability of the doxorubicin-carrier peptide conjugate in whole human blood is assayed as described in Example 1 , supra, prior to evaluation of its in vivo toxicity (lethality studies) and chemotherapeutic activity in nude mice bearing subcutaneous resistant tumors such as the human breast cancer MCF-7/Adr.
- Example 10 Pro-apoptopic protein-carrier peptide prodrug
- the construct includes a transport peptide that carries the pro-apoptotic protein into the nucleus of the target cell and the pro-apoptotic protein granzyme B.
- Granzyme B is purified to homogeneity from the YT natural killer cell line (Harris et al., 1998, J. Biol. Chem. 273:27364-27373).
- the recombinant enzyme is expressed and purified from the yeast Pichia pastoris (Sun et al., 1999, Biochem.
- the construct of granzyme B and the transport peptide is prepared by standard recombinant techniques.
- the amino terminus of the transport peptide is fused to the carboxy terminus of granzyme B.
- the conjugate is tested in vitro for its apoptosis- inducing properties on different tumor cell types.
- Pro-caspase 3 activation assays as well as DNA fragmentation are used to check its activity (Sun et al., 1999, supra).
- a tumor-specific prodrug formulation of the construct is prepared as described in Example 9, supra.
- a PEG-Leu-Ala-Leu-Ala-Leu derivative of the transport peptide is first prepared and then conjugated to granzyme B.
- Leu-Ala-Leu-PEG derivative of the transport peptide is prepared and then conjugated to granzyme B.
- the pro-apoptopic effect of the granzyme B prodrug could be reinforced by the administration of doxorubicin. This could also be a way to overcome resistance to doxorubicin, which often is associated with a defect in the induction of apoptosis (Dive, 1997, J. Int. Med. 242:139-145; Haq and Zanke, 1998, Cancer Metast. Rev. 17, 233-239;
- the granzyme B prodrug is administered with any of the doxorubicin prodrugs described above.
- a doxorubicin prodrug is prepared comprising the PEG-Ala-Leu-Ala-Leu derivative of the transport peptide.
- doxorubicin is conjugated to the transport peptide by a peptide spacer that is capable of being specifically cleaved by the serine protease granzyme B within a cell. The spacer is developed based on the known specificity of granzyme B.
- the two prodrugs are administered sequentially to allow intratumoral accumulation of granzyme B prior to uptake of the granzyme B-sensitive doxorubicin construct.
- a dual prodrug formulation of doxorubicin and the granzyme is administered sequentially to allow intratumoral accumulation of granzyme B prior to uptake of the granzyme B-sensitive doxorubicin construct.
- doxorubicin is linked to the transport peptide construct via an ester or a peptide spacer that remains stable in tumor conditioned media as well as in the presence of granzyme B, but is sensitive to other intracellular hydrolases.
- the present invention is not to be limited in scope by the exemplified embodiments, which are intended as illustrations of single aspects of the invention, and any compositions and methods which are functionally equivalent are within the scope of the invention. Indeed, various modifications of the invention in addition to those described above will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01957808A EP1286700A2 (en) | 2000-06-01 | 2001-05-29 | Tumor activated prodrug compounds |
JP2001587810A JP2003534387A (en) | 2000-06-01 | 2001-05-29 | Tumor activating prodrug compounds and methods for their production and use |
AU2001279630A AU2001279630A1 (en) | 2000-06-01 | 2001-05-29 | Tumor activated prodrug compounds |
CA002408103A CA2408103A1 (en) | 2000-06-01 | 2001-05-29 | Tumor activated prodrug compounds and methods of making and using the same |
US10/296,954 US20040014652A1 (en) | 2000-06-01 | 2001-05-29 | Tumor activated prodrug compounds and methods of making and using the same |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20899600P | 2000-06-01 | 2000-06-01 | |
US60/208,996 | 2000-06-01 | ||
EP00870130 | 2000-06-15 | ||
EP00870130.2 | 2000-06-15 | ||
EP00870306.8 | 2000-12-18 | ||
EP00870306 | 2000-12-18 | ||
EP01957808A EP1286700A2 (en) | 2000-06-01 | 2001-05-29 | Tumor activated prodrug compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001091798A2 true WO2001091798A2 (en) | 2001-12-06 |
WO2001091798A3 WO2001091798A3 (en) | 2002-12-05 |
Family
ID=27440072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/006106 WO2001091798A2 (en) | 2000-06-01 | 2001-05-29 | Tumor activated prodrug compounds |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1286700A2 (en) |
WO (1) | WO2001091798A2 (en) |
Cited By (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001062300A2 (en) * | 2000-02-24 | 2001-08-30 | Genentech, Inc. | Caspase activated prodrugs therapy |
WO2002047730A2 (en) * | 2000-11-06 | 2002-06-20 | Asilomar Pharmaceuticals, Inc | Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins |
WO2002060488A1 (en) * | 2001-01-30 | 2002-08-08 | Universite Catholique De Louvain | Anti-tumor compounds |
US6652864B1 (en) | 1998-12-21 | 2003-11-25 | Asilomar Pharmaceuticals, Inc. | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
EP1470152A1 (en) * | 2002-01-29 | 2004-10-27 | Welgene Pharmaceuticals, Inc. | Peptides for increasing transfection efficiency |
FR2858936A1 (en) * | 2003-08-22 | 2005-02-25 | Diatos | New active compound precursor, useful as therapeutic or diagnostic agent or tracer, includes cleavable component that increases half-life in the circulation, attached through hydrophilic spacer |
EP1674113A1 (en) * | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol) |
EP1765403A2 (en) * | 2004-05-10 | 2007-03-28 | University of Utah Research Foundation | Combined active and passive targeting of biologically active agents |
US7214767B2 (en) * | 2005-05-25 | 2007-05-08 | Hiroshi Kanno | VHL peptide |
WO2007105027A1 (en) * | 2006-03-10 | 2007-09-20 | Diatos | Anticancer drugs conjugated to antibody via an enzyme cleavable linker |
WO2007047995A3 (en) * | 2005-10-21 | 2007-10-04 | Catalyst Biosciences Inc | Modified proteases that inhibit complement activation |
US7722863B2 (en) * | 2002-08-23 | 2010-05-25 | Multimmune Gmbh | Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells |
EP2190861A2 (en) * | 2007-08-22 | 2010-06-02 | The Regents of the University of California | Activatable binding polypeptides and methods of identification and use thereof |
WO2010081173A2 (en) | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
EP2208501A1 (en) * | 2009-01-14 | 2010-07-21 | University of Ulsan Foundation For Industry Cooperation | Anticancer prodrug sensitive to target protease |
US8124051B2 (en) * | 2003-02-19 | 2012-02-28 | Rutgers, The State University Of New Jersey | Complex drug delivery composition and method for treating cancer |
US8232251B2 (en) | 1998-12-21 | 2012-07-31 | Manzanita Pharmaceuticals, Inc. | Compounds for delivery of therapeutic and imaging moieties to nerve cells |
US8476232B2 (en) | 2006-08-31 | 2013-07-02 | Hoffman-La Roche Inc. | Method for the production of conjugates of insulin-like growth factor-1 and poly(ethylene glycol) |
US8552158B2 (en) | 2006-08-31 | 2013-10-08 | Hoffmann-La Roche Inc. | Method for the production of insulin-like growth factor-1 |
WO2014197612A1 (en) * | 2013-06-04 | 2014-12-11 | Cytomx Therapeutics, Inc. | Compositions and methods for conjugating activatable antibodies |
US9120853B2 (en) | 2012-04-27 | 2015-09-01 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
EP2398494A4 (en) * | 2009-02-23 | 2015-10-28 | Cytomx Therapeutics Inc | Proproteins and methods of use thereof |
CN105531605A (en) * | 2013-09-12 | 2016-04-27 | 帝斯曼知识产权资产管理有限公司 | Ocular device |
AU2013202755B2 (en) * | 2007-08-22 | 2016-05-12 | Cytomx Therapeutics, Inc. | Activatable binding polypeptides and methods of identification and use thereof |
US9540440B2 (en) | 2013-10-30 | 2017-01-10 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
EP2532676B1 (en) | 2007-08-15 | 2017-03-22 | Bayer Pharma Aktiengesellschaft | Protease-regulated antibody |
US9737623B2 (en) | 2013-12-11 | 2017-08-22 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
AU2016213702B2 (en) * | 2007-08-22 | 2018-05-17 | Cytomx Therapeutics, Inc. | Activatable binding polypeptides and methods of identification and use thereof |
US10138272B2 (en) | 2014-01-31 | 2018-11-27 | Cytomx Therapeutics, Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
US10179817B2 (en) | 2015-05-04 | 2019-01-15 | Cytomx Therapeutics, Inc. | Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof |
US10233244B2 (en) | 2015-05-04 | 2019-03-19 | Cytomx Therapeutics, Inc. | Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof |
US10261083B2 (en) | 2013-01-04 | 2019-04-16 | Cytomx Therapeutics, Inc. | Compositions and methods for detecting protease activity in biological systems |
US10301380B2 (en) | 2012-06-22 | 2019-05-28 | Cytomx Therapeutics, Inc. | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
US10336824B2 (en) | 2015-03-13 | 2019-07-02 | Cytomx Therapeutics, Inc. | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof |
US10513558B2 (en) | 2015-07-13 | 2019-12-24 | Cytomx Therapeutics, Inc. | Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof |
US10611845B2 (en) | 2012-09-25 | 2020-04-07 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
US10669337B2 (en) | 2014-07-25 | 2020-06-02 | Cytomx Therapeutics, Inc. | Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same |
RU2727836C2 (en) * | 2013-07-25 | 2020-07-24 | Сайтомкс Терапьютикс, Инк. | Multispecific antibodies, multispecific activated antibodies and methods of their application |
US10745481B2 (en) | 2015-05-04 | 2020-08-18 | Cytomx Therapeutics, Inc. | Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof |
US10800850B2 (en) | 2000-10-09 | 2020-10-13 | Cytomx Therapeutics, Inc. | Therapeutic antibodies |
US10894821B2 (en) | 2012-06-22 | 2021-01-19 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and methods of using the same |
US11046759B2 (en) | 2015-01-20 | 2021-06-29 | Cytomx Therapeutics, Inc. | Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof |
US11117968B2 (en) | 2016-11-03 | 2021-09-14 | Bristol-Myers Squibb Company | Activatable anti-CTLA-4 antibodies and uses thereof |
US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
US11230610B2 (en) | 2016-12-09 | 2022-01-25 | Seagen Inc. | Bivalent antibodies masked by coiled coils |
US11365233B2 (en) | 2020-04-10 | 2022-06-21 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
WO2022136586A1 (en) | 2020-12-22 | 2022-06-30 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
WO2022167664A1 (en) | 2021-02-07 | 2022-08-11 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
US11472889B2 (en) | 2017-10-14 | 2022-10-18 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
US11667687B2 (en) | 2021-03-16 | 2023-06-06 | Cytomx Therapeutics, Inc. | Masked activatable interferon constructs |
US11814410B2 (en) | 2013-09-25 | 2023-11-14 | Cytomx Therapeutics, Inc. | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
US11897928B2 (en) | 2018-07-18 | 2024-02-13 | Manzanita Pharmaceuticals, Inc. | Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996005863A1 (en) * | 1994-08-19 | 1996-02-29 | La Region Wallonne | Compounds, pharmaceutical composition and diagnostic device comprising same and their use |
-
2001
- 2001-05-29 WO PCT/EP2001/006106 patent/WO2001091798A2/en active Application Filing
- 2001-05-29 EP EP01957808A patent/EP1286700A2/en not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996005863A1 (en) * | 1994-08-19 | 1996-02-29 | La Region Wallonne | Compounds, pharmaceutical composition and diagnostic device comprising same and their use |
Non-Patent Citations (9)
Title |
---|
CALICETI P ET AL: "PREPARATION AND PROPERTIES OF MONOMETHOXY POLY(ETHYLENE GLYCOL) DOXORUBICIN CONJUGATES LINKED BY AN AMINO ACID OR A PEPTIDE AS SPACER" FARMACO, SOCIETA CHIMICA ITALIANA, PAVIA, IT, vol. 48, no. 7, 1 July 1993 (1993-07-01), pages 919-932, XP000371926 ISSN: 0014-827X * |
CHARI R.V.J.: "Targeted delivery of chemotherapeutics: Tumor - activated prodrug therapy." ADVANCED DRUG DELIVERY REVIEWS, (6 APR 1998) 31/1-2 (89-104). , XP002204748 * |
CHARI, R. V. J. (1) ET AL: "Integration of SB-408075 into combination treatments of human colon xenograft models of SCID mice." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 2000) NO. 41, PP. 291. MEETING INFO.: 91ST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. SAN FRANCISCO, CALIFORNIA, USA APRIL 01-05, 2000 , XP002204745 * |
CHARI, R. V. J. ET AL: "C242-DM1: A tumor - activated prodrug that shows exceptional activity in human colon tumor xenograft models at non-toxic doses." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 1998) VOL. 39, PP. 643. MEETING INFO.: 89TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH NEW ORLEANS, LOUISIANA, USA MARCH 28-APRIL 1, 1998 AMERICAN, XP002204746 * |
LAMBERT, J. M. ET AL: "Pharmacokinetics, in vivo stability, and toxicity of the tumor - activated prodrug, C242-DM1, a novel colorectal cancer agent." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 1998) VOL. 39, PP. 522. MEETING INFO.: 89TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH NEW ORLEANS, LOUISIANA, USA MARCH 28-APRIL 1, 1998 AMERICAN, XP002204747 * |
NICHIFOR, MARIETA ET AL: "Macromolecular prodrugs of 5-fluorouracil. 2: Enzymic degradation" J. CONTROLLED RELEASE (1996), 39(1), 79-92 , XP002204749 * |
TROUET A ET AL: "Extracellularly tumor - activated prodrugs fo the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies." CANCER RESEARCH, (2001 APR 1) 61 (7) 2843-6. , XP002204750 * |
TROUET, ANDRE (1) ET AL: "CPI-0004Na: An extracellularly tumor - activated prodrug of doxorubicin." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 2000) NO. 41, PP. 522. MEETING INFO.: 91ST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. SAN FRANCISCO, CALIFORNIA, USA APRIL 01-05, 2000 , XP002204744 * |
WIEBE, L. I. ET AL: "Concepts for the design of anti-HIV nucleoside prodrugs for treating cephalic HIV infection" ADVANCED DRUG DELIVERY REVIEWS (1999), 39(1-3), 63-80 , XP002204743 * |
Cited By (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8232251B2 (en) | 1998-12-21 | 2012-07-31 | Manzanita Pharmaceuticals, Inc. | Compounds for delivery of therapeutic and imaging moieties to nerve cells |
US8138155B2 (en) | 1998-12-21 | 2012-03-20 | Manzanita Pharmaceuticals, Inc. | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
US7678378B2 (en) | 1998-12-21 | 2010-03-16 | Manzanita Pharmaceuticals, Inc. | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
US7718605B2 (en) | 1998-12-21 | 2010-05-18 | Manzanita Pharmaceuticals, Inc. | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
US6887861B1 (en) | 1998-12-21 | 2005-05-03 | Asilomar Pharmaceuticals, Inc. | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
US6652864B1 (en) | 1998-12-21 | 2003-11-25 | Asilomar Pharmaceuticals, Inc. | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
WO2001062300A2 (en) * | 2000-02-24 | 2001-08-30 | Genentech, Inc. | Caspase activated prodrugs therapy |
WO2001062300A3 (en) * | 2000-02-24 | 2002-04-25 | Paul J Carter | Caspase activated prodrugs therapy |
US10800850B2 (en) | 2000-10-09 | 2020-10-13 | Cytomx Therapeutics, Inc. | Therapeutic antibodies |
WO2002047730A3 (en) * | 2000-11-06 | 2003-07-31 | Asilomar Pharmaceuticals Inc | Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins |
WO2002047730A2 (en) * | 2000-11-06 | 2002-06-20 | Asilomar Pharmaceuticals, Inc | Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins |
WO2002060488A1 (en) * | 2001-01-30 | 2002-08-08 | Universite Catholique De Louvain | Anti-tumor compounds |
EP1470152A1 (en) * | 2002-01-29 | 2004-10-27 | Welgene Pharmaceuticals, Inc. | Peptides for increasing transfection efficiency |
EP1470152A4 (en) * | 2002-01-29 | 2006-11-29 | Welgene Pharmaceuticals Inc | Peptides for increasing transfection efficiency |
US7297759B2 (en) | 2002-01-29 | 2007-11-20 | Welgene, Inc. | Peptides for increasing transfection efficiency |
US7722863B2 (en) * | 2002-08-23 | 2010-05-25 | Multimmune Gmbh | Use of granzyme b as an hsp70/hsp70 peptide dependent inducer of apoptosis in tumor cells |
US8124051B2 (en) * | 2003-02-19 | 2012-02-28 | Rutgers, The State University Of New Jersey | Complex drug delivery composition and method for treating cancer |
JP2007503382A (en) * | 2003-08-22 | 2007-02-22 | ディアトス (ソシエテ アノニム) | Possible activation of high molecular weight prodrugs |
WO2005021043A3 (en) * | 2003-08-22 | 2006-06-15 | Diatos | High-molecular-mass prodrugs |
WO2005021043A2 (en) * | 2003-08-22 | 2005-03-10 | Diatos | High-molecular-mass prodrugs |
FR2858936A1 (en) * | 2003-08-22 | 2005-02-25 | Diatos | New active compound precursor, useful as therapeutic or diagnostic agent or tracer, includes cleavable component that increases half-life in the circulation, attached through hydrophilic spacer |
EP1765403A2 (en) * | 2004-05-10 | 2007-03-28 | University of Utah Research Foundation | Combined active and passive targeting of biologically active agents |
EP1765403A4 (en) * | 2004-05-10 | 2011-03-30 | Univ Utah Res Found | Combined active and passive targeting of biologically active agents |
WO2006066891A3 (en) * | 2004-12-22 | 2007-05-31 | Hoffmann La Roche | Conjugates of insulin-like growth factor-1 (igf-1) and poly(ethylene glycol) |
EA011284B1 (en) * | 2004-12-22 | 2009-02-27 | Ф.Хоффманн-Ля Рош Аг | Conjugates of insulin-like growth factor-1 (igf-1) and poly(ethylene glycol) |
WO2006066891A2 (en) * | 2004-12-22 | 2006-06-29 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor-1 (igf-1) and poly(ethylene glycol) |
EP1674113A1 (en) * | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol) |
US9724425B2 (en) | 2004-12-22 | 2017-08-08 | Hoffmann-La Roche Inc. | Conjugates of insulin-like growth factor-1 and poly(ethylene glycol) |
US7214767B2 (en) * | 2005-05-25 | 2007-05-08 | Hiroshi Kanno | VHL peptide |
US9795655B2 (en) | 2005-10-21 | 2017-10-24 | Catalyst Biosciences, Inc. | Modified MT-SP1 proteases that inhibit complement activation |
CN101340928B (en) * | 2005-10-21 | 2011-12-21 | 催化剂生物科学公司 | Modified proteases that inhibit complement activation |
WO2007047995A3 (en) * | 2005-10-21 | 2007-10-04 | Catalyst Biosciences Inc | Modified proteases that inhibit complement activation |
EP2433642A3 (en) * | 2005-10-21 | 2012-07-11 | Catalyst Biosciences, Inc. | Modified proteases that inhibit complement activation |
WO2007105027A1 (en) * | 2006-03-10 | 2007-09-20 | Diatos | Anticancer drugs conjugated to antibody via an enzyme cleavable linker |
US8476232B2 (en) | 2006-08-31 | 2013-07-02 | Hoffman-La Roche Inc. | Method for the production of conjugates of insulin-like growth factor-1 and poly(ethylene glycol) |
US8552158B2 (en) | 2006-08-31 | 2013-10-08 | Hoffmann-La Roche Inc. | Method for the production of insulin-like growth factor-1 |
EP2532676B1 (en) | 2007-08-15 | 2017-03-22 | Bayer Pharma Aktiengesellschaft | Protease-regulated antibody |
AU2018203095B2 (en) * | 2007-08-22 | 2020-09-10 | Cytomx Therapeutics, Inc. | Activatable binding polypeptides and methods of identification and use thereof |
EP2190861A4 (en) * | 2007-08-22 | 2011-03-30 | Univ California | Activatable binding polypeptides and methods of identification and use thereof |
EP2190861A2 (en) * | 2007-08-22 | 2010-06-02 | The Regents of the University of California | Activatable binding polypeptides and methods of identification and use thereof |
US20120237512A1 (en) * | 2007-08-22 | 2012-09-20 | Patrick Daugherty | Activatable Binding Polypeptides and Methods of Identification and Use Thereof |
US8529898B2 (en) * | 2007-08-22 | 2013-09-10 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
US8541203B2 (en) * | 2007-08-22 | 2013-09-24 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
US11028162B2 (en) | 2007-08-22 | 2021-06-08 | The Regents Of The University Of California | Methods for manufacturing activatable binding polypeptides comprising matrix metalloprotease cleavable moieties |
US20120237977A1 (en) * | 2007-08-22 | 2012-09-20 | Patrick Daugherty | Activatable Binding Polypeptides and Methods of Identification and Use Thereof |
EP3492488A1 (en) * | 2007-08-22 | 2019-06-05 | The Regents of The University of California | Activatable binding polypeptides and methods of identification and use thereof |
AU2020281135B2 (en) * | 2007-08-22 | 2023-02-23 | Cytomx Therapeutics, Inc. | Activatable binding polypeptides and methods of identification and use thereof |
AU2016213702C1 (en) * | 2007-08-22 | 2018-11-29 | Cytomx Therapeutics, Inc. | Activatable binding polypeptides and methods of identification and use thereof |
AU2013202755B2 (en) * | 2007-08-22 | 2016-05-12 | Cytomx Therapeutics, Inc. | Activatable binding polypeptides and methods of identification and use thereof |
US10077300B2 (en) | 2007-08-22 | 2018-09-18 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
AU2016213702B2 (en) * | 2007-08-22 | 2018-05-17 | Cytomx Therapeutics, Inc. | Activatable binding polypeptides and methods of identification and use thereof |
AU2016225810B2 (en) * | 2009-01-12 | 2018-05-24 | Cytomx Therapeutics, Inc | Modified Antibody Compositions, Methods of Making and Using Thereof |
RU2636046C2 (en) * | 2009-01-12 | 2017-11-17 | Сайтомкс Терапьютикс, Инк | Modified antibodies composition, methods of production and application |
EP2385955A4 (en) * | 2009-01-12 | 2013-02-13 | Cytomx Therapeutics Llc | Modified antibody compositions, methods of making and using thereof |
EP2385955A2 (en) * | 2009-01-12 | 2011-11-16 | CytomX Therapeutics, LLC | Modified antibody compositions, methods of making and using thereof |
CN102482347B (en) * | 2009-01-12 | 2017-04-26 | 希托马克斯医疗有限责任公司 | Modified antibody compositions, and methods of making and using thereof |
CN106995495A (en) * | 2009-01-12 | 2017-08-01 | 希托马克斯医疗有限责任公司 | Modified antibodies composition and its preparation and application |
AU2018214147B2 (en) * | 2009-01-12 | 2020-06-04 | Cytomx Therapeutics, Inc | Modified Antibody Compositions, Methods of Making and Using Thereof |
US10875913B2 (en) | 2009-01-12 | 2020-12-29 | Cytomx Therapeutics, Inc. | Methods of treatment using activatable anti-EGFR antibodies |
AU2020203143B2 (en) * | 2009-01-12 | 2023-03-16 | Cytomx Therapeutics, Inc | Modified antibody compositions, methods of making and using thereof |
EP3543256A1 (en) * | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
CN102482347A (en) * | 2009-01-12 | 2012-05-30 | 希托马克斯医疗有限责任公司 | Modified antibody compositions, and methods of making and using thereof |
US9453078B2 (en) | 2009-01-12 | 2016-09-27 | Cytomx Therapeutics, Inc. | Modified antibody compositions, methods of making and using thereof |
WO2010081173A2 (en) | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
US10059762B2 (en) | 2009-01-12 | 2018-08-28 | Cytomx Therapeutics, Inc. | Anti-EGFR activatable antibodies |
AU2010203353B2 (en) * | 2009-01-12 | 2016-06-16 | Cytomx Therapeutics, Inc | Modified antibody compositions, methods of making and using thereof |
AU2016225810C1 (en) * | 2009-01-12 | 2018-09-20 | Cytomx Therapeutics, Inc | Modified Antibody Compositions, Methods of Making and Using Thereof |
US10118961B2 (en) | 2009-01-12 | 2018-11-06 | Cytomx Therapeutics, Inc. | Modified antibody containing the cleavable peptide with the amino acid sequence TGRGPSWV |
EP2208501A1 (en) * | 2009-01-14 | 2010-07-21 | University of Ulsan Foundation For Industry Cooperation | Anticancer prodrug sensitive to target protease |
US10513549B2 (en) | 2009-02-23 | 2019-12-24 | Cytomx Therapeutics, Inc. | Cleavage-activatable interferon-alpha proprotein |
EP2398494A4 (en) * | 2009-02-23 | 2015-10-28 | Cytomx Therapeutics Inc | Proproteins and methods of use thereof |
US9889211B2 (en) | 2012-04-27 | 2018-02-13 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
RU2713121C2 (en) * | 2012-04-27 | 2020-02-03 | Сайтомкс Терапьютикс, Инк. | Activated antibodies which bind to epidermal growth factor receptor, and methods for use thereof |
US9120853B2 (en) | 2012-04-27 | 2015-09-01 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
US9545442B2 (en) | 2012-04-27 | 2017-01-17 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
US10709799B2 (en) | 2012-04-27 | 2020-07-14 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
US11890354B2 (en) | 2012-04-27 | 2024-02-06 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods thereof |
US10301380B2 (en) | 2012-06-22 | 2019-05-28 | Cytomx Therapeutics, Inc. | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
US10894821B2 (en) | 2012-06-22 | 2021-01-19 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and methods of using the same |
US10611845B2 (en) | 2012-09-25 | 2020-04-07 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
US11867695B2 (en) | 2013-01-04 | 2024-01-09 | Cytomx Therapeutics, Inc. | Compositions and methods for detecting protease activity in biological systems |
US11035859B2 (en) | 2013-01-04 | 2021-06-15 | Cytomx Therapeutics, Inc. | Compositions and methods for detecting protease activity in biological systems |
US10261083B2 (en) | 2013-01-04 | 2019-04-16 | Cytomx Therapeutics, Inc. | Compositions and methods for detecting protease activity in biological systems |
WO2014197612A1 (en) * | 2013-06-04 | 2014-12-11 | Cytomx Therapeutics, Inc. | Compositions and methods for conjugating activatable antibodies |
US9517276B2 (en) | 2013-06-04 | 2016-12-13 | Cytomx Therapeutics, Inc. | Compositions and methods for conjugating activatable antibodies |
RU2727836C2 (en) * | 2013-07-25 | 2020-07-24 | Сайтомкс Терапьютикс, Инк. | Multispecific antibodies, multispecific activated antibodies and methods of their application |
US11161906B2 (en) | 2013-07-25 | 2021-11-02 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
CN105531605A (en) * | 2013-09-12 | 2016-04-27 | 帝斯曼知识产权资产管理有限公司 | Ocular device |
US11814410B2 (en) | 2013-09-25 | 2023-11-14 | Cytomx Therapeutics, Inc. | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
US10533053B2 (en) | 2013-10-30 | 2020-01-14 | Cytomx Therapeutics, Inc. | Nucleic acids encoding activatable antibodies that bind epidermal growth factor receptor |
US11180562B2 (en) | 2013-10-30 | 2021-11-23 | Cytomx Therapeutics, Inc. | Method of treating or delaying progression of an epidermal growth factor receptor (EGFR)-related disorder by administering activatable EGFR-binding antibodies |
US9540440B2 (en) | 2013-10-30 | 2017-01-10 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
US10568977B2 (en) | 2013-12-11 | 2020-02-25 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
US9737623B2 (en) | 2013-12-11 | 2017-08-22 | Cytomx Therapeutics, Inc. | Antibodies that bind activatable antibodies and methods of use thereof |
US10138272B2 (en) | 2014-01-31 | 2018-11-27 | Cytomx Therapeutics, Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
US11028126B2 (en) | 2014-01-31 | 2021-06-08 | Cytomx Therapeutics, Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
US11884746B2 (en) | 2014-01-31 | 2024-01-30 | Cytomx Therapeutics, Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
US10669337B2 (en) | 2014-07-25 | 2020-06-02 | Cytomx Therapeutics, Inc. | Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same |
US11802158B2 (en) | 2014-07-25 | 2023-10-31 | Cytomx Therapeutics, Inc. | Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same |
US11046759B2 (en) | 2015-01-20 | 2021-06-29 | Cytomx Therapeutics, Inc. | Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof |
US11472875B1 (en) | 2015-01-20 | 2022-10-18 | Cytomx Therapeutics, Inc. | Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof |
US11548943B2 (en) | 2015-01-20 | 2023-01-10 | Cytomx Therapeutics, Inc. | Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof |
US11548944B2 (en) | 2015-01-20 | 2023-01-10 | Cytomx Therapeutics, Inc. | Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof |
US10336824B2 (en) | 2015-03-13 | 2019-07-02 | Cytomx Therapeutics, Inc. | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof |
US11174316B2 (en) | 2015-03-13 | 2021-11-16 | Cytomx Therapeutics, Inc. | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof |
US10669339B2 (en) | 2015-03-13 | 2020-06-02 | Cytomx Therapeutics, Inc. | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof |
US11753466B2 (en) | 2015-05-04 | 2023-09-12 | Cytomx Therapeutics, Inc. | Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof |
US10233244B2 (en) | 2015-05-04 | 2019-03-19 | Cytomx Therapeutics, Inc. | Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof |
US10179817B2 (en) | 2015-05-04 | 2019-01-15 | Cytomx Therapeutics, Inc. | Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof |
US10745481B2 (en) | 2015-05-04 | 2020-08-18 | Cytomx Therapeutics, Inc. | Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof |
US11267896B2 (en) | 2015-05-04 | 2022-03-08 | Cytomx Therapeutics, Inc. | Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof |
US10513558B2 (en) | 2015-07-13 | 2019-12-24 | Cytomx Therapeutics, Inc. | Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof |
US11117968B2 (en) | 2016-11-03 | 2021-09-14 | Bristol-Myers Squibb Company | Activatable anti-CTLA-4 antibodies and uses thereof |
US11230610B2 (en) | 2016-12-09 | 2022-01-25 | Seagen Inc. | Bivalent antibodies masked by coiled coils |
US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
US11472889B2 (en) | 2017-10-14 | 2022-10-18 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
US11859010B2 (en) | 2017-10-14 | 2024-01-02 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
US11897928B2 (en) | 2018-07-18 | 2024-02-13 | Manzanita Pharmaceuticals, Inc. | Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof |
US11365233B2 (en) | 2020-04-10 | 2022-06-21 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
WO2022136586A1 (en) | 2020-12-22 | 2022-06-30 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
WO2022167664A1 (en) | 2021-02-07 | 2022-08-11 | Cobiores Nv | Compounds comprising a tetrapeptidic moiety |
US11667687B2 (en) | 2021-03-16 | 2023-06-06 | Cytomx Therapeutics, Inc. | Masked activatable interferon constructs |
Also Published As
Publication number | Publication date |
---|---|
EP1286700A2 (en) | 2003-03-05 |
WO2001091798A3 (en) | 2002-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040014652A1 (en) | Tumor activated prodrug compounds and methods of making and using the same | |
EP1286700A2 (en) | Tumor activated prodrug compounds | |
US10189876B2 (en) | Cell penetrating peptides for intracellular delivery of molecules | |
US10118944B2 (en) | Cell penetrating peptides for intracellular delivery of molecules | |
AU754617B2 (en) | Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances | |
Ahrens et al. | Peptides and peptide conjugates: therapeutics on the upward path | |
JP3607201B2 (en) | FAP-activated antitumor compound | |
RU2722449C2 (en) | Poly-ligand medicinal conjugates and use thereof | |
WO2000033888A2 (en) | Prodrug compounds and process for preparation thereof | |
CA2265476A1 (en) | Conjugates useful in the treatment of prostate cancer | |
BRPI0620806A2 (en) | peptides useful as cell penetration peptides | |
JP2017002039A (en) | Novel polyfunctional compound for pharmaceutical purpose | |
Hudecz et al. | Medium‐sized peptides as built in carriers for biologically active compounds | |
US6696274B2 (en) | Ligand for enhancing oral and CNS delivery of biological agents | |
CA2408103A1 (en) | Tumor activated prodrug compounds and methods of making and using the same | |
US20050181474A1 (en) | Transport peptides and uses therefor | |
KR20210052473A (en) | Peptides with immunomodulatory properties | |
CA2247432A1 (en) | Targeting macromolecular prodrugs to t lymphocytes | |
KR20040008135A (en) | Tumour targeting prodrugs activated by metallo matrixproteinases | |
CA2408387A1 (en) | A ligand for enhancing oral and cns delivery of biological agents | |
US20220072084A1 (en) | Therapeutic nanoconjugates and uses thereof | |
AU2021217787A1 (en) | Treatment of PANX1 associates diseases | |
KR20180010235A (en) | Biologically cleavable tetrapeptide linkers | |
CA2398395A1 (en) | Conjugates targeted to target receptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2408103 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 587810 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001957808 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001957808 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10296954 Country of ref document: US |